<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6762200</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0223017</article-id><article-id pub-id-type="publisher-id">PONE-D-19-08554</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Chromatographic Techniques</subject><subj-group><subject>Column Chromatography</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Chromatographic Techniques</subject><subj-group><subject>Planar Chromatography</subject><subj-group><subject>Thin-Layer Chromatography</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Spectrum analysis techniques</subject><subj-group><subject>NMR spectroscopy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Proteases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Proteases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>West Nile virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>West Nile virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>West Nile virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>West Nile virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Materials Science</subject><subj-group><subject>Materials</subject><subj-group><subject>Amorphous Solids</subject><subj-group><subject>Gels</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Materials Science</subject><subj-group><subject>Materials</subject><subj-group><subject>Mixtures</subject><subj-group><subject>Gels</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme Inhibitors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Cytotoxicity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Cytotoxicity</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Discovery of novel West Nile Virus protease inhibitor based on isobenzonafuranone and triazolic derivatives of eugenol and indan-1,3-dione scaffolds</article-title><alt-title alt-title-type="running-head">Discovery of novel West Nile Virus protease inhibitor</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>de Oliveira</surname><given-names>Andr&#x000e9; S.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Gazolla</surname><given-names>Poliana A. R.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Oliveira</surname><given-names>Ana Fl&#x000e1;via C. da S.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Wagner L.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>de S. Viol</surname><given-names>L&#x000ed;via C.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maia</surname><given-names>Ang&#x000e9;lica F. da S.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Edjon G.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0579-8157</contrib-id><name><surname>da Silva</surname><given-names>&#x000cd;talo E. P.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mendes</surname><given-names>Tiago A. de Oliveira</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Software</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Adalberto M.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dias</surname><given-names>Roberto S.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Cynthia C.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9210-690X</contrib-id><name><surname>Pol&#x000ea;to</surname><given-names>Marcelo D.</given-names></name><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Teixeira</surname><given-names>R&#x000f3;bson R.</given-names></name><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2275-5768</contrib-id><name><surname>de Paula</surname><given-names>Sergio O.</given-names></name><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Departamento de Biologia Geral, Universidade Federal de Vi&#x000e7;osa, Vi&#x000e7;osa, MG, Brazil</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Instituto Federal de Educa&#x000e7;&#x000e3;o, Ci&#x000ea;ncia e Tecnologia do Norte de Minas Gerais, Fazenda Biribiri, MG, Brazil</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Departamento de Bioqu&#x000ed;mica Biologia Molecular, Universidade Federal de Vi&#x000e7;osa, Vi&#x000e7;osa, MG, Brazil</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Departamento de Qu&#x000ed;mica, Universidade Federal de Vi&#x000e7;osa, Vi&#x000e7;osa, MG, Brazil</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Instituto Federal de Educa&#x000e7;&#x000e3;o, Ci&#x000ea;ncia e Tecnologia Catarinense, Araquari, SC, Brazil</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Andrei</surname><given-names>Graciela</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Katholieke Universiteit Leuven Rega Institute for Medical Research, BELGIUM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>depaula@ufv.br</email> (SOP); <email>robsonr.teixeira@ufv.br</email> (RRT)</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>14</volume><issue>9</issue><elocation-id>e0223017</elocation-id><history><date date-type="received"><day>12</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 de Oliveira et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>de Oliveira et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0223017.pdf"/><abstract><p>The West Nile Virus (WNV) NS2B-NS3 protease is an attractive target for the development of therapeutics against this arboviral pathogen. In the present investigation, the screening of a small library of fifty-eight synthetic compounds against the NS2-NB3 protease of WNV is described. The following groups of compounds were evaluated: 3-(2-aryl-2-oxoethyl)isobenzofuran-1(3<italic>H</italic>)-ones; eugenol derivatives bearing 1,2,3-triazolic functionalities; and indan-1,3-diones with 1,2,3-triazolic functionalities. The most promising of these was a eugenol derivative, namely 4-(3-(4-allyl-2-methoxyphenoxy)-propyl)-1-(2-bromobenzyl)-1<italic>H</italic>-1,2,3-triazole (<bold>35</bold>), which inhibited the protease with IC<sub>50</sub> of 6.86 <italic>&#x003bc;</italic>mol L<sup>-1</sup>. Enzyme kinetic assays showed that this derivative of eugenol presents competitive inhibition behaviour. Molecular docking calculations predicted a recognition pattern involving the residues His<sup>51</sup> and Ser<sup>135</sup>, which are members of the catalytic triad of the WNV NS2B-NS3 protease.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003593</institution-id><institution>Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dias</surname><given-names>Roberto S.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004901</institution-id><institution>Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de Minas Gerais</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0579-8157</contrib-id><name><surname>da Silva</surname><given-names>&#x000cd;talo E. P.</given-names></name></principal-award-recipient></award-group><funding-statement>The following authors of this paper received scholarships during this research: ASO and AFCSO from the Instituto Federal de Educa&#x000e7;&#x000e3;o, Ci&#x000ea;ncia e Tecnologia do Norte de Minas Gerais (IFNMG &#x02013; <ext-link ext-link-type="uri" xlink:href="http://www.ifnmg.edu.br">www.ifnmg.edu.br</ext-link>); EGS, IEPS and AMS from the Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de Minas Gerais (FAPEMIG &#x02013; <ext-link ext-link-type="uri" xlink:href="http://www.fapemig.br">www.fapemig.br</ext-link>); RSD, TAOM and SOP from the Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPQ &#x02013; <ext-link ext-link-type="uri" xlink:href="http://www.memoria.cnpq.br">www.memoria.cnpq.br</ext-link>); PARG, WLP, LCSV and AFSM from the Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior (CAPES &#x02013; <ext-link ext-link-type="uri" xlink:href="http://www.capes.gov.br">www.capes.gov.br</ext-link>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="10"/><table-count count="1"/><page-count count="25"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>The West Nile Virus (WNV) is a member of the same family as the Dengue virus (DENV), Zika virus (ZIKV) and Yellow Fever virus (YFV), the <italic>Flaviviridae</italic> family, <italic>Flavivirus</italic> genus. They are arboviruses that present RNA as a genome [<xref rid="pone.0223017.ref001" ref-type="bibr">1</xref>]. Diseases caused by <italic>Flavivirus</italic> are the major causes of fatality in poverty-stricken regions across Africa, Asia and some parts of the Americas. The combined potential health risk associated with arthropod-borne viruses like DENV, WNV, and ZIKV is enormous. These arboviruses are either emerging or re-emerging in many regions [<xref rid="pone.0223017.ref002" ref-type="bibr">2</xref>].</p><p>Three WNV strains are known to be capable of causing unforeseen and large epidemics, leading to serious public health problems. Since 2004, lineages 1 and 3 have been circulating in Europe and, since 2010, beginning in a major epidemic in Greece, lineage 2 has been circulating in several European countries. [<xref rid="pone.0223017.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0223017.ref004" ref-type="bibr">4</xref>]. The WNV crossed the Atlantic and reached the Western Hemisphere in 1999, when a group of patients with encephalitis was reported in the New York City metropolitan area. Within three years, the virus spread to Canada and Mexico, followed by animal cases in Central and South America [<xref rid="pone.0223017.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0223017.ref006" ref-type="bibr">6</xref>]. Recently, the first human case of WNV was reported in Brazil, with the development of encephalitis. It is possible that sporadic cases or small groups of the WNV disease had already occurred in different regions of the country without being properly diagnosed [<xref rid="pone.0223017.ref007" ref-type="bibr">7</xref>].</p><p>WNV is a genetically and geographically diverse virus. Four or five distinct WNV genetic lines have been proposed, based on phylogenetic analyses of published isolates. Their genomes differ from each other by about 20&#x02013;25%, and are well correlated with the geographic point of isolation [<xref rid="pone.0223017.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0223017.ref010" ref-type="bibr">10</xref>]. They are enveloped viruses whose genome consists of single-stranded, positive-polarity RNA approximately 11 kb. This RNA contains a single open reading frame encoding a precursor polyprotein, which is processed by viral and host proteases, giving rise to three structural proteins: capsidial protein (C), envelope glycoprotein (E) and pre-membrane/membrane protein (prM/M); and seven non-structural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5, which are involved in the replicative cycle of the virus[<xref rid="pone.0223017.ref011" ref-type="bibr">11</xref>]. Viral protease performs the cleavage of some sites: NS2A-NS2B, NS2B-NS3, NS3-NS4A and NS4B-NS5. It also cleaves the signal sequences at the C-prM position and the NS4A-NS4B, within NS2A, and within the NS3 itself [<xref rid="pone.0223017.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0223017.ref013" ref-type="bibr">13</xref>].</p><p>Despite the tremendous efforts invested in <italic>Flavivirus</italic> research, no clinically approved antiviral chemotherapeutics are available for humans, and disease treatment is limited to supportive care [<xref rid="pone.0223017.ref013" ref-type="bibr">13</xref>]. Inhibition of viral enzymes has proved to be one important approach toward the development of antiviral therapies [<xref rid="pone.0223017.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0223017.ref013" ref-type="bibr">13</xref>&#x02013;<xref rid="pone.0223017.ref015" ref-type="bibr">15</xref>]. Non-structural proteins encoded by these RNA viruses are essential for their replication and maturation, and thus may offer ideal targets for developing antiviral drugs [<xref rid="pone.0223017.ref002" ref-type="bibr">2</xref>]. <italic>Flavivirus</italic> genomes are translated into a single polyprotein that needs to be cleaved by viral and host proteases. Because it processes most of the polyprotein cleavages, viral protease is necessary and essential for virus replication [<xref rid="pone.0223017.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0223017.ref017" ref-type="bibr">17</xref>].</p><p>Considering the premises, the screening of a small library of fifty-eight synthetic compounds against the NS2-NB3 protease of WNV is described in the present investigation. The following groups of compounds were evaluated: (<bold>I</bold>) 3-(2-aryl-2-oxoethyl)isobenzofuran-1(3<italic>H</italic>)-ones; (<bold>II</bold>) eugenol derivatives bearing 1,2,3-triazolic functionalities; and (<bold>III</bold>) indan-1,3-diones with 1,2,3-triazolic functionalities. <xref ref-type="fig" rid="pone.0223017.g001">Fig 1</xref> displays the general structures of the evaluated compounds.</p><fig id="pone.0223017.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g001</object-id><label>Fig 1</label><caption><title>General structures of compounds evaluated as inhibitors of WNV NS2-NB3 protease.</title><p>3-(2-aryl-2-oxoethyl)isobenzofuran-1(3<italic>H</italic>)-ones (<bold>I</bold>); eugenol derivatives bearing 1,2,3-triazolic functionalities (<bold>II</bold>); indan-1,3-diones with 1,2,3-triazolic functionalities (<bold>III</bold>).</p></caption><graphic xlink:href="pone.0223017.g001"/></fig><p>The isobenzofuran-1-(3<italic>H</italic>)-ones, 1,2,3-triazolic derivatives, eugenol, and indan-1,3-diones are substances that have been described in the literature as being endowed with antiviral activities [<xref rid="pone.0223017.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0223017.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0223017.ref028" ref-type="bibr">28</xref>]. Isobenzofuran-1-(3<italic>H</italic>) -one derivatives have several biological activities [<xref rid="pone.0223017.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0223017.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="pone.0223017.ref035" ref-type="bibr">35</xref>], highlighting antiviral action for HIV[<xref rid="pone.0223017.ref018" ref-type="bibr">18</xref>]. Indan-1,3-diones derivatives have been specifically associated with antiviral activity. Studies have indicated efficient action of indan-1,3-diones against the enzyme integrase of the HIV-1 virus [<xref rid="pone.0223017.ref036" ref-type="bibr">36</xref>]; against the structure of human papillomavirus (HPV) [<xref rid="pone.0223017.ref037" ref-type="bibr">37</xref>&#x02013;<xref rid="pone.0223017.ref039" ref-type="bibr">39</xref>]; and also against the Hepatitis C virus (HCV) protease [<xref rid="pone.0223017.ref040" ref-type="bibr">40</xref>], and recently for WNV protease [<xref rid="pone.0223017.ref041" ref-type="bibr">41</xref>]. Eugenol has been tested against the Herpes virus (HSV), HSV-1 (five viral isolates) and HSV-2 (five viral isolates), providing complete protection against one isolate of each type, HSV-1 and 2, and protection between 16.5% and 87.7% for the remaining isolates [<xref rid="pone.0223017.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0223017.ref023" ref-type="bibr">23</xref>]. The triazole ring was associated with the molecules due to the antimicrobial activity already described for 1,2,3-triazole compounds, especially studies that demonstrated antiviral action against the Dengue virus [<xref rid="pone.0223017.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0223017.ref020" ref-type="bibr">20</xref>]. This fact prompted the authors to evaluate the effect of the compounds presenting general structures (<bold>I</bold>), (<bold>II</bold>) and (<bold>III</bold>) on the NS2-NB3 WNV protease.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Synthesis</title><p>Solvents were purchased from Vetec (Rio de Janeiro, Brazil). Benzyl alcohols, pent-4-yn-1-ol, methanesulfonyl chloride, sodium azide, triethylamine, propargyl bromide, acetophenones, and indan-1,3-dione were procured from Sigma Aldrich (St. Louis, MO, United States) and used as received. Eugenol was extracted via hydrodistillation from cloves purchased in the local market in Vi&#x000e7;osa, Minas Gerais state, Brazil, and subsequently purified by column chromatography (<italic>vide infra</italic>). <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were recorded on a Varian Mercury 300 MNR Spectrometer (Varian, Palo Alto, CA, United States) at 300 MHz and 75 MHz, respectively, using CDCl<sub>3</sub>, C<sub>6</sub>D<sub>6</sub> or DMSO-<italic>d</italic><sub><italic>6</italic></sub> as solvents. NMR data are presented as follows: chemical shift (<italic>&#x003b4;</italic>) in ppm, multiplicity, the number of protons, and <italic>J</italic> values in Hertz (Hz). Multiplicities are shown as the following abbreviations: s (singlet), brs (broad singlet), d (doublet), d<sub>ap</sub> (apparent doublet), dd (doublet of a doublets), t (triplet), brd (broad doublet), ddt<sub>ap</sub> (apparent doublet of doublets of triplets), q (quartet), quint (quintet), and m (multiplet). Some signals in the <sup>13</sup>C NMR spectra were described as multiplets due to the <sup>19</sup>F-<sup>13</sup>C coupling. IR spectra were obtained using a Varian 660-IR equipped with GladiATR (Varian, Palo Alto, CA, USA) scanning from 4000 to 500 cm<sup>&#x02212;1</sup>. Analytical thin-layer chromatography analysis was conducted on aluminum-backed, pre-coated silica gel plates using different solvent systems. TLC plates were visualized using potassium permanganate solution, phosphomolybdic acid solution and/or UV light. Flash column chromatography was performed using silica gel 60 (60&#x02013;230 mesh). Melting points were determined using a MQAPF-302 melting point apparatus (Microquimica, Santa Catarina, Brazil) and are uncorrected. Solvents were dried using standard procedures described in the literature [<xref rid="pone.0223017.ref042" ref-type="bibr">42</xref>].</p><sec id="sec004"><title>Synthesis of 3-(2-oxo-aryl)-isobenzofuran-1-(3<italic>H</italic>)-ones 1&#x02013;18</title><p>The preparation of compounds <bold>1</bold>&#x02013;<bold>18</bold> (<xref ref-type="fig" rid="pone.0223017.g002">Fig 2</xref>) was carried out via ZrOCl<sub>2</sub>&#x000b7;8H<sub>2</sub>O catalyzed condensation reactions between phthalaldehydic acid and different acetophenones as previously reported [<xref rid="pone.0223017.ref043" ref-type="bibr">43</xref>].</p><fig id="pone.0223017.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g002</object-id><label>Fig 2</label><caption><title>Structures of compounds <italic>1</italic>&#x02013;<italic>18</italic>, <italic>23</italic>&#x02013;<italic>49</italic>, and <italic>51</italic>&#x02013;<italic>63</italic>.</title></caption><graphic xlink:href="pone.0223017.g002"/></fig></sec><sec id="sec005"><title>Extraction and purification of eugenol (19)</title><p>Eugenol (<bold>19</bold>) was extracted via hydrodistillation from dried flower buds of <italic>Eugenia caryophyllata</italic>, commonly known as cloves, purchased in the local market in Vi&#x000e7;osa, Minas Gerais state, Brazil. Thus, 60.0 g of cloves were mixed with 500 mL of distilled water in a round-bottom flask which was connected to the hydrodistillation apparatus. The mixture was heated for three hours. The obtained hydrolate was transferred to a separatory funnel and the aqueous layer was extracted with dichloromethane (3 x 30 mL). The organic extracts were combined and the resulting organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting oil was submitted to column chromatography eluted with hexane-ethyl acetate (6:1 v/v). The described procedure afforded 7.12 g of eugenol (<bold>19</bold>), which corresponded to approximately a 12% yield in relation to the initial mass of cloves used in the extraction process.</p></sec><sec id="sec006"><title>Synthesis of 4-allyl-2-methoxy-1-(prop-2-yn-1-yloxy)benzene (20)</title><p>A 50 mL round-bottom flask was charged with eugenol (<bold>19</bold>) (1.20 g, 7.32 mmol), sodium hydroxide (0.313 g, 7.83 mmol) and 25 mL of methanol. The resulting mixture was heated to 40 <sup>o</sup>C and magnetically stirred for 30 minutes. After this time, methanol was removed under reduced pressure and 10.0 mL of anhydrous ethanol was added for the removal of the residual water. The ethanol was removed under reduced pressure. Then, the round-bottom flask, under a nitrogen atmosphere, was charged with anhydrous acetonitrile (25.0 mL) and propargyl bromide (800 <italic>&#x003bc;</italic>L, 8.79 mmol) was added slowly. The mixture was magnetically stirred at room temperature for 18 hours. TLC analysis revealed the completion of the reaction after this time. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between 25.0 mL of sodium hydroxide solution (0.1 mol L<sup>-1</sup>) and 25 mL of diethyl ether. The layers were separated and the aqueous phase was extracted with diethyl ether (2 x 25.0 mL). The organic extracts were combined and the resulting organic layer was washed with brine (25.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography eluted with hexane-ethyl acetate (6:1 v/v). The described procedure afforded 1.29 g (6.37 mmol, 87% yield) of compound <bold>20</bold>.</p></sec><sec id="sec007"><title>Synthesis of pent-4-yn-1-yl methanesulfonate (21)</title><p>Pent-4-yn-1-ol (1.68 g, 20.0 mmol) and dichloromethane (20 mL) were added to a 100 mL round-bottom flask under nitrogen atmosphere. The mixture was cooled to -50&#x000b0;C and triethylamine (5.60 mL, 40.0 mmol) was added. After that, methanesulfonyl chloride was added slowly (2.32 mL, 30.0 mmol) to the reaction mixture under continuous stirring. The progress of the reaction was monitored by TLC. After completion of it, 10 mL of distilled water were added. The organic phase was washed with 1% HCl solution (3 x 15 mL) followed by saturated aqueous NaHCO<sub>3</sub> (3 x 5 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography eluted with hexane-ethyl acetate-dicloromethane (3:1:3 v/v) to give compound <bold>21</bold> in 92% yield (3.00 g, 18.0 mmol).</p></sec><sec id="sec008"><title>Synthesis 4-allyl-2-methoxy-1-(pent-4-yn-1-yloxy)benzene (22)</title><p>This compound was prepared using a similar procedure to that described for the preparation of compound <bold>20</bold>. In this case, the alkylating agent corresponded to compound <bold>21</bold>. Substance <bold>22</bold> was obtained in 78% yield (1.64 g, 7.13 mmol) after purification by column chromatography eluted with hexane-ethyl acetate (6:1 v/v).</p></sec><sec id="sec009"><title>Synthesis of compounds 23&#x02013;51 exemplified by the synthesis of compound 4-((4-allyl-2-methoxyphenoxy)methyl)-1-benzyl-1<italic>H</italic>-1,2,3-triazole (23)</title><p>A 10 mL round bottom flask was charged with 4-allyl-2-methoxy-1-(prop-2-yn-1-yloxy)benzene (<bold>20</bold>) (0.150 g, 0.740 mmol), benzyl azide (0.0990g; 0.740 mmol), sodium ascorbate (0.0590 g, 0.300 mmol), 1.00 mL of etanol and 1.00 mL of distilled water. Then, CuSO<sub>4</sub>&#x000b7;5H<sub>2</sub>O (0.0370 g, 0.150 mmol) was added. The reaction mixture was vigorously stirred at room temperature. After completion of the reaction, as noticed was by TLC analysis, the mixture was extracted with dichloromethane (3 x 10.0 mL). The organic extracts were combined and the resulting organic layer was washed with aqueous sodium carbonate saturated solution, dried over anhydrous sodium sulphate, filtrated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v). Compound <bold>23</bold> was obtained in 91% yield (0.228g, 0.680 mmol). Selected IR and NMR spectra is show at A-C Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p>Compounds <bold>24</bold>&#x02013;<bold>51</bold> were prepared using a procedure similar to that described for the synthesis of <bold>23</bold>. The structures of these compounds were confirmed by NMR (<sup>1</sup>H and <sup>13</sup>C), and IR analyses and are supported by the following data.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-fluorobenzyl)-1<italic>H</italic>-1,2,3-triazole (24)</bold></p><p>White solid, m.p. 92.1&#x02013;92.7&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.39 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at D-F Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-chlorobenzyl)-1<italic>H</italic>-1,2,3-triazole (25)</bold></p><p>White solid, m.p. 112.3&#x02013;112.6&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.37 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at G-I Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-bromobenzyl)-1<italic>H</italic>-1,2,3-triazole (26)</bold></p><p>White solid, m.p. 119.1&#x02013;120.2&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.59 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at J-L Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-iodobenzyl)-1<italic>H</italic>-1,2,3-triazole (27)</bold></p><p>White solid, m.p. 129.2&#x02013;131.1&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.37 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at M-O Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-nitrobenzyl)-1<italic>H</italic>-1,2,3-triazole (28)</bold></p><p>White solid, m.p. 120.9&#x02013;121.9&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v) TLC: R<sub>f</sub> = 0.14 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at P-R Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-methoxybenzyl)-1<italic>H</italic>-1,2,3-triazole (29)</bold></p><p>White solid, m.p. 92.4&#x02013;93.1&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.36 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at S-U Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-(trifluoromethoxy)benzyl)-1<italic>H</italic>-1,2,3-triazole (30)</bold></p><p>White solid, m.p. 126.4&#x02013;127.3&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.49 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at V-W Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-(trifluoromethyl)benzyl)-1<italic>H</italic>-1,2,3-triazole (31)</bold></p><p>White solid, m.p. 142.7&#x02013;143.0&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.43 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at Y-AA Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(3,4-difluorobenzyl)-1H-1,2,3-triazole (32)</bold></p><p>White solid, m.p. 104.9&#x02013;105.2&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.30 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AB-AD Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2,5-dichlorobenzyl)-1<italic>H</italic>-1,2,3-triazole (33)</bold></p><p>White solid, m.p. 87.9&#x02013;88.4&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.59 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AE-AG Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-methylbenzyl)-1<italic>H</italic>-1,2,3-triazole (34)</bold></p><p>White solid, m.p. 81.4&#x02013;82,3&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.66 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AH-AJ Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2-bromobenzyl)-1<italic>H</italic>-1,2,3-triazole (35)</bold></p><p>White solid, m.p. 67.5&#x02013;68.6&#x000b0;C, TLC: R<sub>f</sub> = 0.70 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AK-AM Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(3-bromobenzyl)-1<italic>H</italic>-1,2,3-triazole (36)</bold></p><p>White solid, m.p. 97.5&#x02013;97.9&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.70 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AN-AP Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-benzyl-1<italic>H</italic>-1,2,3-triazole (37)</bold></p><p>White solid, m.p. 71.4&#x02013;72.6&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane- (3:1:3 v/v), TLC: R<sub>f</sub> = 0.16 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AQ-AS Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-fluorobenzyl)-1<italic>H</italic>-1,2,3-triazole (38)</bold></p><p>White solid, m.p. 96.4&#x02013;96,8&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.21 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AT-AV Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-chlorobenzyl)-1<italic>H</italic>-1,2,3-triazole (39)</bold></p><p>White solid, m.p. 81.8&#x02013;82.2&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.46 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AX-AY Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-bromobenzyl)-1<italic>H</italic>-1,2,3-triazole (40)</bold></p><p>White solid, m.p. 89.4&#x02013;90.3&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.46 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at AZ-BB Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-iodobenzyl)-1<italic>H</italic>-1,2,3-triazole (41)</bold></p><p>White solid, m.p. 98.3&#x02013;99.2&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.45 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at BC-BE Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-nitrobenzyl)-1<italic>H</italic>-1,2,3-triazole (42)</bold></p><p>White solid, m.p. 79.7&#x02013;80.4&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> 0.29 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at BF-BH Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methoxybenzyl)-1<italic>H</italic>-1,2,3-triazole (43)</bold></p><p>White solid, m.p. 88.9&#x02013;90.4&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.22 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at BI-BK Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-(trifluoromethoxy)benzyl)-1<italic>H</italic>-1,2,3-triazole (44)</bold></p><p>White solid, m.p. 93.4&#x02013;94.9&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.49 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at BL-BN Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-(trifluoromethyl)benzyl)-1<italic>H</italic>-1,2,3-triazole (45)</bold></p><p>White solid, m.p. 111.3&#x02013;112.5&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.50 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at BO-BQ Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(3,4-difluorobenzyl)-1<italic>H</italic>-1,2,3-triazole (46)</bold></p><p>White solid, m.p. 97.1&#x02013;97.8&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.41 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at BR-BT Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methylbenzyl)-1<italic>H</italic>-1,2,3-triazole (47)</bold></p><p>White solid, m.p. 59.6&#x02013;60.9&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.42 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at BU-BX Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(2-bromobenzyl)-1<italic>H</italic>-1,2,3-triazole (48)</bold></p><p>White solid, m.p. 47.8&#x02013;49.1&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.61 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at BW-BZ Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(3-bromobenzyl)-1<italic>H</italic>-1,2,3-triazole (49)</bold></p><p>White solid, m.p. 65.9&#x02013;67.1&#x000b0;C, purified by column chromatography eluted with hexane-ethyl acetate-dichloromethane (3:1:3 v/v), TLC: R<sub>f</sub> = 0.32 (hexane-ethyl acetate-dichloromethane 3:1:3 v/v). Selected IR and NMR spectra is show at CA-CC Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p></sec><sec id="sec010"><title>2,2-di(prop-2-yn-1-yl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (50)</title><p>To a mixture of indan-1,3-dione (0.146 g, 1.00 mmol) and distilled water (40 mL), it was added potassium hydroxide (0.140 g, 0.250 mmol) and propargyl bromide (0.364 mL, 4.00 mmol). The resulting mixture was magnetically stirred at 40 <sup>o</sup>C for 24h. After this time, the reaction mixture was cooled down to room temperature and it was neutralized with aqueous solution of HCl 0.100 mol L<sup>-1</sup>. The aqueous phase was extracted with ethyl acetate (3 x 20 mL). The organic extracts were combined and the resulting organic phase was washed with brine (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Compound <bold>50</bold> was not submitted to any purification process and it was obtained in 93% yield (0.207 g, 0.930 mmol).</p></sec><sec id="sec011"><title>Synthesis of compounds 51&#x02013;63 exemplified by the synthesis of 2,2-bis((1-(4-bromobenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (51)</title><p>To a 10 mL round bottom-flask, containing 1.5 mL of dichloromethane and 1.5 mL of distilled water, it was added 4-bromobenzylazide (168.8 mg, 0.800 mmol), alkyne <bold>50</bold> (88.8 mg, 0.400 mmol), and sodium ascorbate (60.0 mg, 0.300 mmol). Then, it was added CuSO<sub>4</sub>&#x000b7;5H<sub>2</sub>O (38.0 mg, 0.150 mmol) and the resulting mixture was vigorously stirred at room temperature for 2 hours. After that, it was added to the reaction mixture sodium carbonate saturated aqueous solution (20 mL) and the resulting aqueous phase was extracted with dichloromethane (3 x 15 mL) followed by ethyl acetate (3 x 15 mL). The organic extracts were combined and the resulting organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica-gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane 3:1:3 v/v. Compound <bold>51</bold> was obtained in 51% yield (143.1 mg, 0.220 mmol). Selected IR and NMR spectra is show at CD-CF Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p>Compounds <bold>52</bold>&#x02013;<bold>63</bold> were synthesized employing a procedure similar to that described for the preparation of <bold>51</bold>. The structures of substances <bold>52</bold>&#x02013;<bold>63</bold> are supported by the following data.</p><p><bold>Data for 2,2-bis((1-(3-bromobenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (52)</bold></p><p>White solid, m.p. 185.6&#x02013;187.2 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.08 (hexane-ethyl acetate-dichloromethane 3:1:1 v/v). Selected IR and NMR spectra is show at CG-CI Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(2-bromobenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (53)</bold></p><p>Pale yellow solid, m.p. 178.4&#x02013;179.7 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichoromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.11 (hexane-ethyl acetate-dichloromethae 3:1:1 v/v). Selected IR and NMR spectra is show at CJ-CL Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(4-chlorobenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (54)</bold></p><p>White solid, m.p. 222.3&#x02013;223.9 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.02 (hexane-ethyl acetate-dichoromethane 3:1:1 v/v). Selected IR and NMR spectra is show at CM-CO Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(4-fluorobenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (55)</bold></p><p>White solid, m.p. 223.0&#x02013;224.5 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.01 (hexane-ethyl acetate-dichoromethane 3:1:1 v/v). Selected IR and NMR spectra is show at CP-CR Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(4-methoxybenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (56)</bold></p><p>White solid, m.p. 118.5&#x02013;119.8 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.01 (hexane-ethyl acetate-dichloromethane 3:1:1 v/v). Selected IR and NMR spectra is show at CS-CU Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(4-trifluoromethoxybenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (57)</bold></p><p>White solid, m.p. 253.7&#x02013;254.5 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.02 (hexane-ethyl acetate-dichloromethane 3:1:1 v/v). Selected IR and NMR spectra is show at CV-CW Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(4-nitrobenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (58)</bold></p><p>White solid, m.p. 271.2&#x02013;272.4 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.01 (hexane-ethyl acetate-dichloromethane 3:1:1 v/v). Selected IR and NMR spectra is show at CY-DA Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(2,4-difluorobenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (59)</bold></p><p>White solid, m.p. 178.3&#x02013;179.5 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.06 (hexane-ethyl acetate-dichloromethane 3:1:1 v/v). Selected IR and NMR spectra is show at DB-DD Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(4-iodobenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (60)</bold></p><p>White solid, m.p. 211.3&#x02013;212.2 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.06 (hexane-ethyl acetate 3:1:1 v/v). Selected IR and NMR spectra is show at DE-DG Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(2-benzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (61)</bold></p><p>White solid, m.p. 161.5&#x02013;162.8 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.05 (hexane-ethyl acetate-dichloromethane 3:1:1 v/v). Selected IR and NMR spectra is show at DH-DJ Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(4-trifluoromethylbenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (62)</bold></p><p>White solid, m.p. 243.7&#x02013;244.6 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.24 (hexane-ethyl acetate-dichloromethane 3:1:1 v/v). Selected IR and NMR spectra is show at DK-DM Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p><p><bold>Data for 2,2-bis((1-(4-methylbenzyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)methyl)-1<italic>H</italic>-indene-1,3(2<italic>H</italic>)-dione (63)</bold></p><p>White solid, m.p. 170.8&#x02013;171.4 <sup>o</sup>C, purified by silica gel column chromatography eluted with hexane-ethyl-acetate-dichloromethane (3:1:1 v/v), TLC: R<sub>f</sub> = 0.08 (hexane-ethyl acetate-dichloromethane 3:1:1 v/vSelected IR and NMR spectra is show at DN-DP Figs in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>.</p></sec></sec><sec id="sec012"><title>Evaluation of the inhibitory activity of compounds 1&#x02013;18, 23&#x02013;49, and 51&#x02013;63 on WNV NS2B-NS3 protease</title><p>In order to assess the activity of the synthesized compounds on WNV NS2B-NS3pro, recombinant WNV NS2B-NS3 protease (catalog number SE-2907, already purified and activated) and fluorescent substrate pERTKR-AMC (catalog number ES013) were purchased from R &#x00026; D Systems (Minneapolis, MN, United States). Compounds <bold>1</bold>&#x02013;<bold>18</bold>, <bold>23</bold>&#x02013;<bold>49</bold>, and <bold>51</bold>&#x02013;<bold>63</bold> were dissolved in pure dimethyl sulfoxide (DMSO); solutions were then diluted in a buffer to obtain working solutions with a final concentration of 1% v/v DMSO. A volume of 50 <italic>&#x003bc;</italic>L of purified NS2B-NS3pro (final concentration of 1 ng <italic>&#x003bc;</italic>L<sup>-1</sup>) diluted in a buffer (50 mmol L<sup>-1</sup> Tris, 30% (v/v) glycerol, pH 9.5) was incubated with 50 <italic>&#x003bc;</italic>L of each compound (final concentration of 16 <italic>&#x003bc;</italic>mol L<sup>-1</sup>) in a 96-well black plate for 30 min at 21&#x02013;22&#x000b0;C. After this time, the assay was initiated by addition of 50 <italic>&#x003bc;</italic>L of the substrate (40 mmol L<sup>-1</sup> &#x02013;initial concentration). A solution containing a buffer and DMSO was used as negative control on the same plate. The blank contained 50 <italic>&#x003bc;</italic>L of the buffer and 100 <italic>&#x003bc;</italic>L of the substrate. The fluorescence intensity was continuously recorded at a 360 nm excitation wavelength and at an emission wavelength of 460 nm using a SpectraMax<sup>&#x000ae;</sup> M5 microplate reader (Molecular Devices, San Jos&#x000e9;, CA, United States). Compounds which effectively inhibited the enzyme were selected for further biological assays. Analyses were performed using Microsoft Excel (Microsoft Office Software) and GraphPad Prism 6 (GraphPad Software Inc.). The assays were conducted in triplicate during three isolated experiments, and the statistical analyses were conducted by utilizing the multiple comparisons of one-way ANOVA.</p></sec><sec id="sec013"><title>Determination of IC<sub>50</sub></title><p>The inhibitory enzymatic activity of compound <bold>35</bold>, the one most active against the WNV NS2-NB3 protease, was evaluated at eight different concentrations (66 <italic>&#x003bc;</italic>mol L<sup>-1</sup>&#x02013;0.5 <italic>&#x003bc;</italic>mol L<sup>-1</sup>) using the protease assay as described above. Fluorescence was measured in triplicate wells at intervals of 30 s for 5 min in three independent experiments. IC<sub>50</sub> values were calculated using GraphPad Prism software 6 (GraphPad Software Inc., San Diego, CA, United States), using four-parameter nonlinear regression analysis (Hill slope method).</p></sec><sec id="sec014"><title>Determination of K<sub>i</sub></title><p>Three different concentrations (2, 4 and 8 <italic>&#x003bc;</italic>mol L<sup>-1</sup>) of inhibitor <bold>35</bold> and five different concentrations of substrate pERTKR-AMC (20, 40, 60, 80, 100 mmol L<sup>-1</sup>) were tested <italic>in vitro</italic> against the WNV protease (37.04 nmol L<sup>-1</sup> protein, 1 ng <italic>&#x003bc;</italic>L<sup>-1</sup>). Fluorescence was measured in triplicate wells at an interval of 30 s. The velocity values (RFU/minute) were then calculated for each substrate/inhibitor pair. K<sub>i</sub> values were calculated with GraphPad Prism software 6 (GraphPad Software Inc., San Diego, CA, United States) with non-linear regression in the competitive inhibition mode of enzyme-kinetics.</p></sec><sec id="sec015"><title>Cytotoxicity assay</title><p>The cytotoxicity of compound <bold>35</bold> was assessed using an MTT assay [<xref rid="pone.0223017.ref044" ref-type="bibr">44</xref>]. VERO cells (5 x 10<sup>4</sup> cells) were seeded in 96-well plates. Each well contained 100 <italic>&#x003bc;</italic>L of each compound solution at different concentrations (1000, 250, 125, 63, 32, 17, 8 and 4 <italic>&#x003bc;</italic>mol L<sup>-1</sup>). The compound was diluted in MEM medium with 2% FBS and 1% DMSO. After 24 h of incubation at 37 <sup>o</sup>C, 100 <italic>&#x003bc;</italic>L of the MTT solution (5%) was added to the wells. After 4 h at 37&#x000b0;C, the MTT solution was removed and 100 <italic>&#x003bc;</italic>L/well of DMSO was added to solubilize the formazan. Absorbance was measured at 550 nm in a microplate reader (Multiskan<sup>&#x02122;</sup> GO Microplate Spectrophotometer&#x02013;ThermoFisher<sup>&#x000ae;</sup>, Waltham, MA, United States). The data were analyzed and CC<sub>50</sub> was determined using GraphPad Prism 6.</p></sec><sec id="sec016"><title>Virucidal assay</title><p>The virucidal assay was performed as described by Oliveira et al. [<xref rid="pone.0223017.ref041" ref-type="bibr">41</xref>].</p></sec><sec id="sec017"><title>Molecular modeling studies</title><p>Ligands were prepared in the Ligprep program (Schr&#x000f6;dinger, New York, NY, United States) [<xref rid="pone.0223017.ref045" ref-type="bibr">45</xref>] employing the OPLS_2005 force field, with protonation states predicted using Epik at pH 9.5 &#x000b1; 2.0. The West Nile Virus protease NS2B-NS3 PDB code 2IJO [<xref rid="pone.0223017.ref046" ref-type="bibr">46</xref>], chosen as the receptor, was prepared with the Protein Preparation Wizard (Schr&#x000f6;dinger, New York, NY, United States), with removal of all waters and addition of hydrogens based on PROPKA calculations at pH 9.5. Docking calculations were performed with the Glide software (Schr&#x000f6;dinger, New York, NY, United States) [<xref rid="pone.0223017.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0223017.ref048" ref-type="bibr">48</xref>], employing the Induced Fit docking methodology [<xref rid="pone.0223017.ref049" ref-type="bibr">49</xref>] and Glide SP. All the software packages used are part of the Schr&#x000f6;dinger Release 2016&#x02013;2 package (Schr&#x000f6;dinger, New York, NY, United States) [<xref rid="pone.0223017.ref050" ref-type="bibr">50</xref>]. A spherical grid with 12 &#x000c5; radius was centered in the Isoleucine 123 residue so that the active site was fully included within the grid. All residues within 5 &#x000c5; from the center were considered flexible. Docking results were ranked based on their docking score and the top ranking poses for each compound were analyzed with the Maestro 10.6 software (Schr&#x000f6;dinger, New York, NY, United States) [<xref rid="pone.0223017.ref051" ref-type="bibr">51</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec018"><title>Results and discussion</title><sec id="sec019"><title>Synthesis of compounds 1&#x02013;18, 23&#x02013;49, and 51&#x02013;63</title><p>The structures of the synthesized compounds are depicted in <xref ref-type="fig" rid="pone.0223017.g002">Fig 2</xref>.</p><p>As previously mentioned, the synthesis of isobenzofuran-(3<italic>H</italic>)-ones <bold>1&#x02013;18</bold> has been previously reported [<xref rid="pone.0223017.ref043" ref-type="bibr">43</xref>].</p><p>For the preparation of compounds <bold>23&#x02013;49</bold>, we initially isolated eugenol (<bold>19</bold>) from dried flower buds of <italic>Eugenia caryophyllata</italic> via hydrodistillation. Subsequently, eugenol (<bold>19</bold>) was submitted to alkylation procedures, affording terminal alkynes <bold>21</bold> and <bold>22</bold> in yields of, respectively, 87% and 78% (<xref ref-type="fig" rid="pone.0223017.g003">Fig 3</xref>).</p><fig id="pone.0223017.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g003</object-id><label>Fig 3</label><caption><title>Preparation of alkylated derivatives of eugenol.</title><p>i) NaOH, CH<sub>3</sub>OH, 40&#x000b0;C; acetonitrile, r.t; ii) NaOH, CH<sub>3</sub>OH, 40 <sup>o</sup>C; acetonitrile, 70 <sup>o</sup>C.</p></caption><graphic xlink:href="pone.0223017.g003"/></fig><p>Then, the CuAAC reactions (click reactions) between benzyl azides (ArCH<sub>2</sub>N<sub>3</sub>) and terminal alkynes <bold>21</bold> and <bold>22</bold> led to the formation of triazolic derivatives <bold>23&#x02013;49</bold> (<xref ref-type="fig" rid="pone.0223017.g004">Fig 4</xref>). The click reactions, in general, took less than one minute for their completion.</p><fig id="pone.0223017.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g004</object-id><label>Fig 4</label><caption><title>Preparation of eugenol derivatives 23&#x02013;49.</title><p>iii) sodium ascorbate (40 mol%), CuSO<sub>4</sub>&#x000b7;5H<sub>2</sub>O (20 mol%), EtOH/H<sub>2</sub>O (1:1 v/v).</p></caption><graphic xlink:href="pone.0223017.g004"/></fig><p>A similar sequence, namely alkylation of indan-1,3-dione followed by click reaction between compound <bold>50</bold> and benzyl azides, was utilized to prepared triazolic compounds <bold>51&#x02013;63</bold> (<xref ref-type="fig" rid="pone.0223017.g005">Fig 5</xref>).</p><fig id="pone.0223017.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g005</object-id><label>Fig 5</label><caption><title>Synthesis of compounds 51&#x02013;63.</title><p>iv) aqueous KOH, then propargyl bromide, 40 <sup>o</sup>C, 24h; v) sodium ascorbate (40 mol%), CuSO<sub>4</sub>&#x000b7;5H<sub>2</sub>O (20 mol%), CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O (1:1 v/v), 2h.</p></caption><graphic xlink:href="pone.0223017.g005"/></fig><p>It should be mentioned that the azides, used in the preparation of compounds <bold>23&#x02013;49</bold> and <bold>51&#x02013;63,</bold> were obtained via the methodology previously described in the literature [<xref rid="pone.0223017.ref052" ref-type="bibr">52</xref>]. Once prepared, the synthesized compounds were submitted to biological assays to evaluate their inhibitory effects against the NS2-NB3 protease of WNV.</p></sec><sec id="sec020"><title>Identification of WNV protease inhibitors</title><p>The <italic>Flavivirus</italic> protease is essential for the processing of the polyprotein which generates the viral proteins required for viral replication and maturation of infectious virions. Therefore, the protease is an ideal target for the discovery of antivirals against <italic>Flavivirus</italic> [<xref rid="pone.0223017.ref053" ref-type="bibr">53</xref>]. In the present investigation, we evaluated the inhibitory activity of fifty-eight compounds against the WNV NS2B-NS3 protease (eighteen 3-(2-oxo-2-aryl)-isobenzofuran-1(3<italic>H</italic>)-ones, compounds <bold>1&#x02013;18</bold>; twenty-seven derivatives of eugenol with triazole rings, compounds <bold>23&#x02013;49</bold>; thirteen derivatives of indan-1,3-diones presenting triazole rings, compounds <bold>51&#x02013;63</bold>, <xref ref-type="fig" rid="pone.0223017.g002">Fig 2</xref>). In this regard, a purified preparation of WNV NS2B3NS3pro and the fluorogenic peptide substrate pERTKR-AMC was utilized.</p><p>Our primary screen resulted in the identification of eighteen compounds (~31% of the evaluated compounds) that exhibited inhibitory effects on protease activity (<xref ref-type="fig" rid="pone.0223017.g006">Fig 6</xref>).</p><fig id="pone.0223017.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g006</object-id><label>Fig 6</label><caption><title>Inhibitory activity screening for WNV protease.</title><p>Fifty-eight compounds were evaluated at the concentration of 16 <italic>&#x003bc;</italic>mol L<sup>-1</sup> against the WNV NS2-NB3 protease. The assays were conducted in triplicate during three isolated experiments (p value &#x0003c; 0.0001).</p></caption><graphic xlink:href="pone.0223017.g006"/></fig><p>Subsequently, we took these eighteen compounds and conducted a secondary screening with further validation based on their relative strengths of inhibition (at least 50%). This resulted in the selection of compound <bold>35</bold>, a eugenol derivative which was utilized in further experiments.</p><p>A derivative of the natural product eugenol capable of significantly inhibiting the activity of the WNV NS2B-NS3 protease was identified. Taking the eugenol derivatives into consideration, we made variations in the size of the carbon chain that links eugenol moiety and the triazole ring. Also, the substitution pattern of the aromatic ring attached to the triazolic portion was varied. These modifications afforded a group of eugenol triazolic derivatives from which was identified the very active compound <bold>35</bold>. It is important to mention that further chemical modifications can be planned regarding the eugenol and triazole fragments so that new derivatives with improved activity may be obtained. Considering that there is no <italic>Flavivirus</italic> protease inhibitor approved for pre-clinical trial [<xref rid="pone.0223017.ref054" ref-type="bibr">54</xref>], the exploitation of the new scaffold herein identified, namely triazolic derivatives of eugenol, would be of considerable importance.</p></sec><sec id="sec021"><title>Determination of IC<sub>50</sub> and Ki values of the enzymatic inhibitory activity of compound 35</title><p>The enzymatic inhibition was evaluated in the presence of varying concentrations (0.5 <italic>&#x003bc;</italic>mol L<sup>-1</sup> to 66 <italic>&#x003bc;</italic>mol L<sup>1</sup>) of compound <bold>35</bold>. A dose-response inhibition was noticed with IC<sub>50</sub> value of 6.86 <italic>&#x003bc;</italic>mol L<sup>-1</sup> (<xref ref-type="fig" rid="pone.0223017.g007">Fig 7</xref>).</p><fig id="pone.0223017.g007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g007</object-id><label>Fig 7</label><caption><title>Enzymatic inhibitory profile of compound 35.</title></caption><graphic xlink:href="pone.0223017.g007"/></fig><p>The enzyme kinetic assay was conducted under five different substrate concentrations and three varying concentrations of compound <bold>35</bold>. We used the Michaelis-Menten equation to find the values of V<sub>MAX</sub> and K<sub>M</sub>; and with these, the Lineweaver-Burk graph was built. Compound <bold>35</bold> showed a decrease of enzymatic V<sub>MAX</sub> and an increase in K<sub>M</sub>, presenting the behaviour of a competitive inhibitor (<xref ref-type="fig" rid="pone.0223017.g008">Fig 8A and 8B</xref>). The K<sub>i</sub> value was 3.06 (&#x000b1; 0.38) <italic>&#x003bc;</italic>mol L<sup>-1</sup>.</p><fig id="pone.0223017.g008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g008</object-id><label>Fig 8</label><caption><title>Enzymatic kinetics of WNV NS2-NB3 protease in the presence of compound 35.</title><p>In <bold>A,</bold> the Michaelis-Menten plot is shown. In <bold>B</bold>, the Lineweaver-Burk plot is presented.</p></caption><graphic xlink:href="pone.0223017.g008"/></fig><p>For compound 35, the enzyme kinetic data showed an increase in the K<sub>M</sub> value, a typical behaviour of competitive inhibitors. In addition, this compound displayed a low K<sub>i</sub> value. In a recent investigation, Balasubramanian and collaborators [<xref rid="pone.0223017.ref053" ref-type="bibr">53</xref>] found eight promising flavivirus protease inhibitors presenting K<sub>i</sub> values within the 0.22 to 6.9 <italic>&#x003bc;</italic>mol L<sup>-1</sup> range. However, the K<sub>i</sub> value may not be analyzed individually. In the study by Balasubramanian and collaborators, a compound presenting low K<sub>i</sub> value (0.22 <italic>&#x003bc;</italic>mol L<sup>-1</sup>) but displaying a CC<sub>50</sub> of 29.16 <italic>&#x003bc;</italic>mol L<sup>-1</sup> was identified [<xref rid="pone.0223017.ref053" ref-type="bibr">53</xref>].</p><p>For the development of new drugs, the World Health Organization (WHO) strongly recommends the use of compounds with pharmacological effects already described and substances already approved for clinical use, so that several steps can be abbreviated in the long validation process [<xref rid="pone.0223017.ref055" ref-type="bibr">55</xref>]. Eugenol (<bold>19</bold>) has been safely used in <italic>in vivo</italic> experiments, and it has been recognized as a safe, effective and inexpensive anesthetic for fish, amphibians and rats [<xref rid="pone.0223017.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0223017.ref057" ref-type="bibr">57</xref>]. Also, the analgesic effect of eugenol (<bold>19</bold>) in different models of pain has been well documented [<xref rid="pone.0223017.ref058" ref-type="bibr">58</xref>&#x02013;<xref rid="pone.0223017.ref062" ref-type="bibr">62</xref>]. A recent work with BALB/c mice used a derivative of eugenol (<bold>19</bold>) to treat visceral Leishmaniasis. This derivative presented low cytotoxicity for macrophages as well as for naive mice with immune-stimulatory activity. Moreover, no biochemical alterations in hepatic and renal enzymes were noticed [<xref rid="pone.0223017.ref063" ref-type="bibr">63</xref>]. Eugenol (<bold>19</bold>) is generally non-allergenic for humans, although in sensitized individuals it may cause a range of tissue reactions from low-grade local to systemic. Low concentrations of eugenol (<bold>19</bold>) are well known to exert local anti-inflammatory, antiseptic, and anesthetic effects on dental pulp. Also, eugenol (<bold>19</bold>) may have antibacterial effects that are beneficial for dental hygiene, being included in materials such as toothpastes and mouthwashes [<xref rid="pone.0223017.ref064" ref-type="bibr">64</xref>&#x02013;<xref rid="pone.0223017.ref066" ref-type="bibr">66</xref>]. All these features make eugenol (<bold>19</bold>), as well as its derivatives, very interesting compounds to be explored in drug development.</p></sec><sec id="sec022"><title>Cytotoxicity assay</title><p>The cytotoxicity of compound <bold>35</bold> on Vero cells was investigated via the colorimetric MTT assay and the determined CC<sub>50</sub> value was 327.20 <italic>&#x003bc;</italic>mol L<sup>-1</sup> (<xref ref-type="fig" rid="pone.0223017.g009">Fig 9</xref>). Luo and collaborators [<xref rid="pone.0223017.ref054" ref-type="bibr">54</xref>] reported the best parameters for the most promising compounds against the protease of <italic>Flavivirus</italic>. They highlighted a compound with low cytotoxicity presenting CC<sub>50</sub> superior to 300 <italic>&#x003bc;</italic>mol L<sup>-1</sup>. Eugenol derivative <bold>35</bold> presented a similar CC<sub>50</sub>, and it can be considered a compound with low cytotoxicity. Therefore, although a very potent inhibitor, this compound presented considerable cytotoxicity.</p><fig id="pone.0223017.g009" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g009</object-id><label>Fig 9</label><caption><title>Dose-response profile of compound 35 on Vero cells.</title></caption><graphic xlink:href="pone.0223017.g009"/></fig></sec><sec id="sec023"><title>Molecular modeling</title><p>Multiple targets and inhibitory mechanisms have been proposed for <italic>Flavivirus</italic> proteases so far [<xref rid="pone.0223017.ref053" ref-type="bibr">53</xref>, <xref rid="pone.0223017.ref054" ref-type="bibr">54</xref>, <xref rid="pone.0223017.ref067" ref-type="bibr">67</xref>, <xref rid="pone.0223017.ref068" ref-type="bibr">68</xref>], which have provided insightful structural information regarding the NS2B-NS3 catalytic site, helping computational-aided drug design efforts even further. For instance, by solving NS2B-NS3&#x02019;s tridimensional structure bound to a peptide-like inhibitor, Erbel and coworkers [<xref rid="pone.0223017.ref069" ref-type="bibr">69</xref>] provided fundamental information regarding the protease fold, catalytic site structure and inhibition mechanisms. As found by others [<xref rid="pone.0223017.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0223017.ref070" ref-type="bibr">70</xref>&#x02013;<xref rid="pone.0223017.ref072" ref-type="bibr">72</xref>], inhibitors often bind to His<sup>51</sup> or to nearby residues such as Asp<sup>75</sup>, Asp<sup>129</sup>, Gly<sup>153</sup> and Tyr<sup>161</sup> (<xref ref-type="supplementary-material" rid="pone.0223017.s002">S1 Fig</xref>), hampering the bond of the substrate to the catalytic site.</p><p>In order to perform our own molecular docking calculations, the crystallographic structure of the NS2B-NS3 protease was obtained from PDB 2IJO, in which NS2B-NS3 is co-crystallized with the WNV protease inhibitor aprotinin. All molecules derived from eugenol were analyzed for their probable three-dimensional binding conformation, binding energy, chemical groups involved, profile of binding and identity of the involved amino acids, as observed in table A in <xref ref-type="supplementary-material" rid="pone.0223017.s001">S1 File</xref>. The predicted recognition mechanism for compound <bold>35</bold> relies on interactions with His<sup>51</sup>, Thr<sup>134</sup>, Ser<sup>135</sup> and Tyr<sup>161</sup>, as represented in <xref ref-type="fig" rid="pone.0223017.g010">Fig 10A</xref>, and the ligand occupies pocket S1 of the catalytic site. The NH<sup>+</sup> of the His<sup>51</sup> ring interacts with the triazole ring of <bold>35</bold> in cation-&#x003c0; and &#x003c0;-&#x003c0; type interactions, and the Tyr<sup>161</sup> ring interacts with the phenyl ring of <bold>35</bold> via &#x003c0;-&#x003c0; type interaction, while a halogen bond can be formed between the Br atom and the OH from Ser<sup>135</sup> or the NH from Thr<sup>134</sup>. It is important to highlight that both His<sup>51</sup> and Ser<sup>135</sup> are members of the catalytic triad of the NS2B-NS3 protease, which might explain the observed competitive inhibitory activity of <bold>35</bold>.</p><fig id="pone.0223017.g010" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.g010</object-id><label>Fig 10</label><caption><title>WNV protease docking with compound 35 and 36.</title><p>The entire protease is shown in lilac, highlighting residues Ser<sup>135</sup> (dark blue), His<sup>51</sup> (orange), and Asp<sup>75</sup> (green). <bold>A.</bold> In white is compound <bold>35</bold>. <bold>B.</bold> In gray is compound <bold>36</bold>. Hydrogen bonds are shown in yellow, halogen bonds are shown in red, T-shape &#x003c0;-&#x003c0; interactions are shown in cyan and cation-&#x003c0; interactions are shown in pink.</p></caption><graphic xlink:href="pone.0223017.g010"/></fig><p>In addition, compound <bold>36</bold> showed no inhibitory activity, despite the fact that the only difference from compound <bold>35</bold> is the position of a bromo substituent (<italic>orto</italic> in <bold>35</bold> and <italic>meta</italic> in <bold>36</bold><italic>)</italic>. Our calculations suggest that the formation of a halogen bond for <bold>36</bold> with bromo in <italic>meta</italic> might induce a more stable conformation for the ligand in which the triazole ring interacts with Gly<sup>153</sup> instead of His<sup>51</sup> and, consequently, leaves the S1 pocket free (<xref ref-type="fig" rid="pone.0223017.g010">Fig 10B</xref>). These results suggest that the bromo substituent in <italic>orto</italic> is pivotal for a proper recognition of compound <bold>35</bold>, along with the cation-&#x003c0; interaction between His<sup>51</sup> and the triazole ring, while the methoxyphenyl ring region might be a suitable target for further improvements.</p></sec><sec id="sec024"><title>Virucidal assay</title><p>To determine whether compound <bold>35</bold> would have antiviral activity for <italic>Flaviviruses</italic>, a virucidal assay was performed with four serotypes of DENV, due to its close evolutionary proximity to WNV and due to the highly conserved NS2B-NS3 fold and sequence. This assay was performed by prior incubation of the compound with each viral strain, followed by its addition to the cell layer for virus adsorption and internalization. Subsequently, the compound-virus solution was removed and antiviral action was observed through the formation of lysis plates. The concentration of test compounds that inhibited 50% of the viral infection (EC<sub>50</sub>) was obtained by nonlinear regression, leading to the calculation of the Selectivity Index (SI).The observed results are presented in <xref rid="pone.0223017.t001" ref-type="table">Table 1</xref>.</p><table-wrap id="pone.0223017.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0223017.t001</object-id><label>Table 1</label><caption><title>CC<sub>50</sub>, EC<sub>50</sub> and SI values of the compound 35 in the presence of DENV-1-4.</title></caption><alternatives><graphic id="pone.0223017.t001g" xlink:href="pone.0223017.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Compound</th><th align="center" rowspan="2" colspan="1">CC<sub>50</sub><break/><italic>&#x003bc;</italic>mol L<sup>-1</sup></th><th align="center" colspan="2" rowspan="1">DENV-1</th><th align="center" colspan="2" rowspan="1">DENV-2</th><th align="center" colspan="2" rowspan="1">DENV-3</th><th align="center" colspan="2" rowspan="1">DENV-4</th></tr><tr><th align="center" rowspan="1" colspan="1">EC<sub>50</sub><break/><italic>&#x003bc;</italic>mol L<sup>-1</sup></th><th align="center" rowspan="1" colspan="1">SI</th><th align="center" rowspan="1" colspan="1">EC<sub>50</sub><break/><italic>&#x003bc;</italic>mol L<sup>-1</sup></th><th align="center" rowspan="1" colspan="1">SI</th><th align="center" rowspan="1" colspan="1">EC<sub>50</sub><break/><italic>&#x003bc;</italic>mol L<sup>-1</sup></th><th align="center" rowspan="1" colspan="1">SI</th><th align="center" rowspan="1" colspan="1">EC<sub>50</sub><break/><italic>&#x003bc;</italic>mol L<sup>-1</sup></th><th align="center" rowspan="1" colspan="1">SI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>35</bold></td><td align="center" rowspan="1" colspan="1">327,20</td><td align="center" rowspan="1" colspan="1">46,57</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">49,20</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">70,10</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">14,17</td><td align="center" rowspan="1" colspan="1">23</td></tr></tbody></table></alternatives></table-wrap><p>The compound had good SI values for DENV-1-3 and a higher value for DENV-4. All together, the results indicate that compound <bold>35</bold> has significant antiviral efficacy and is a promising antiviral candidate for <italic>Flavivirus</italic>.</p></sec></sec><sec sec-type="conclusions" id="sec025"><title>Conclusion</title><p>In this work, a small library of fifty-eight synthetic compounds (isobenzofuran-1(3<italic>H</italic>)-ones and triazolic derivatives of eugenol and indandione) were screened against the WNV NS2B-NS3 protease. By modifying the structure of the natural product eugenol to produce 1,2,3-triazolic derivatives, a compound presenting low cytotoxicity and considerable inhibitory protease activity was identified. Compound <bold>35</bold> corresponds to 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(2-bromobenzyl)-1<italic>H</italic>-1,2,3-triazole. In addition, molecular docking calculations suggested that the inhibition mechanism relies on interactions between His<sup>51</sup>, Thr<sup>134</sup>, Ser<sup>135</sup> and Tyr<sup>161</sup>. The virucidal assay with DENV-1-4 strains indicates that compound <bold>35</bold> is a promising lead compound for antiviral activity against <italic>Flavivirus</italic>. Taken together, our results provide insightful information for further development of <italic>Flavivirus</italic> protease inhibitors via rational drug design. Efforts towards this end are under way in our laboratories.</p></sec><sec sec-type="supplementary-material" id="sec026"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0223017.s001"><label>S1 File</label><caption><p><bold>Table A. Docking of the compounds 23 to 49 with WNV protease.</bold> The entire protease is shown in lilac, highlighting residues Ser135 (dark blue), His51 (orange), and Asp75 (green). The compound is show in red. FigsA-DP Figs. Selected IR and NMR spectra.</p><p>(PDF)</p></caption><media xlink:href="pone.0223017.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0223017.s002"><label>S1 Fig</label><caption><title>Inhibition mechanisms observed between WNV NS2B-NS3 protease cocrystallized peptide-like molecules obtained from Protein Data Bank.</title><p>A. 2YOL; B. 3E90; C. 5IDK; and D. 2FP7.</p><p>(TIFF)</p></caption><media xlink:href="pone.0223017.s002.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0223017.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Martin-Acebes</surname><given-names>MA</given-names></name>, <name><surname>Vazquez-Calvo</surname><given-names>A</given-names></name>, <name><surname>Saiz</surname><given-names>JC</given-names></name>. <article-title>Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses</article-title>. <source>Prog Lipid Res</source>. <year>2016</year>;<volume>64</volume>:<fpage>123</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.plipres.2016.09.005</pub-id> .<?supplied-pmid 27702593?><pub-id pub-id-type="pmid">27702593</pub-id></mixed-citation></ref><ref id="pone.0223017.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Bhakat</surname><given-names>S</given-names></name>, <name><surname>Karubiu</surname><given-names>W</given-names></name>, <name><surname>Jayaprakash</surname><given-names>V</given-names></name>, <name><surname>Soliman</surname><given-names>ME</given-names></name>. <article-title>A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses</article-title>. <source>Eur J Med Chem</source>. <year>2014</year>;<volume>87</volume>:<fpage>677</fpage>&#x02013;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2014.10.010</pub-id> .<?supplied-pmid 25305334?><pub-id pub-id-type="pmid">25305334</pub-id></mixed-citation></ref><ref id="pone.0223017.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Chaskopoulou</surname><given-names>A</given-names></name>, <name><surname>Dovas</surname><given-names>CI</given-names></name>, <name><surname>Chaintoutis</surname><given-names>SC</given-names></name>, <name><surname>Kashefi</surname><given-names>J</given-names></name>, <name><surname>Koehler</surname><given-names>P</given-names></name>, <name><surname>Papanastassopoulou</surname><given-names>M</given-names></name>. <article-title>Detection and early warning of West Nile Virus circulation in Central Macedonia, Greece, using sentinel chickens and mosquitoes</article-title>. <source>Vector Borne Zoonotic Dis</source>. <year>2013</year>;<volume>13</volume>(<issue>10</issue>):<fpage>723</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1089/vbz.2012.1176</pub-id> .<?supplied-pmid 23919609?><pub-id pub-id-type="pmid">23919609</pub-id></mixed-citation></ref><ref id="pone.0223017.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Chaskopoulou</surname><given-names>A</given-names></name>, <name><surname>L'Ambert</surname><given-names>G</given-names></name>, <name><surname>Petric</surname><given-names>D</given-names></name>, <name><surname>Bellini</surname><given-names>R</given-names></name>, <name><surname>Zgomba</surname><given-names>M</given-names></name>, <name><surname>Groen</surname><given-names>TA</given-names></name>, <etal>et al</etal>
<article-title>Ecology of West Nile virus across four European countries: review of weather profiles, vector population dynamics and vector control response.</article-title>
<source>Parasit Vectors</source>. <year>2016</year>;<volume>9</volume>(<issue>1</issue>):<fpage>482</fpage>
<pub-id pub-id-type="doi">10.1186/s13071-016-1736-6</pub-id>
<?supplied-pmid 27590848?><pub-id pub-id-type="pmid">27590848</pub-id></mixed-citation></ref><ref id="pone.0223017.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Morales</surname><given-names>MA</given-names></name>, <name><surname>Barrandeguy</surname><given-names>M</given-names></name>, <name><surname>Fabbri</surname><given-names>C</given-names></name>, <name><surname>Garcia</surname><given-names>JB</given-names></name>, <name><surname>Vissani</surname><given-names>A</given-names></name>, <name><surname>Trono</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>West Nile virus isolation from equines in Argentina, 2006</article-title>. <source>Emerg Infect Dis</source>. <year>2006</year>;<volume>12</volume>(<issue>10</issue>):<fpage>1559</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.3201/eid1210.060852</pub-id>
<?supplied-pmid 17176571?><pub-id pub-id-type="pmid">17176571</pub-id></mixed-citation></ref><ref id="pone.0223017.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Kleinschmidt-DeMasters</surname><given-names>BK</given-names></name>, <name><surname>Beckham</surname><given-names>JD</given-names></name>. <article-title>West Nile Virus Encephalitis 16 Years Later.</article-title>
<source>Brain Pathol</source>. <year>2015</year>;<volume>25</volume>(<issue>5</issue>):<fpage>625</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1111/bpa.12280</pub-id> .<?supplied-pmid 26276026?><pub-id pub-id-type="pmid">26276026</pub-id></mixed-citation></ref><ref id="pone.0223017.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Ometto</surname><given-names>T</given-names></name>, <name><surname>Durigon</surname><given-names>EL</given-names></name>, <name><surname>de Araujo</surname><given-names>J</given-names></name>, <name><surname>Aprelon</surname><given-names>R</given-names></name>, <name><surname>de Aguiar</surname><given-names>DM</given-names></name>, <name><surname>Cavalcante</surname><given-names>GT</given-names></name>, <etal>et al</etal>
<article-title>West Nile virus surveillance, Brazil, 2008&#x02013;2010</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2013</year>;<volume>107</volume>(<issue>11</issue>):<fpage>723</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/trstmh/trt081</pub-id> .<?supplied-pmid 24008895?><pub-id pub-id-type="pmid">24008895</pub-id></mixed-citation></ref><ref id="pone.0223017.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Flatau</surname><given-names>E</given-names></name>, <name><surname>Kohn</surname><given-names>D</given-names></name>, <name><surname>Daher</surname><given-names>O</given-names></name>, <name><surname>Varsano</surname><given-names>N</given-names></name>. <article-title>West Nile fever encephalitis</article-title>. <source>Isr J Med Sci</source>. <year>1981</year>;<volume>17</volume>(<issue>11</issue>):<fpage>1057</fpage>&#x02013;<lpage>9</lpage>. .<?supplied-pmid 6274825?><pub-id pub-id-type="pmid">6274825</pub-id></mixed-citation></ref><ref id="pone.0223017.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Bakonyi</surname><given-names>T</given-names></name>, <name><surname>Hubalek</surname><given-names>Z</given-names></name>, <name><surname>Rudolf</surname><given-names>I</given-names></name>, <name><surname>Nowotny</surname><given-names>N</given-names></name>. <article-title>Novel flavivirus or new lineage of West Nile virus, central Europe</article-title>. <source>Emerg Infect Dis</source>. <year>2005</year>;<volume>11</volume>(<issue>2</issue>):<fpage>225</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.3201/eid1102.041028</pub-id>
<?supplied-pmid 15752439?><pub-id pub-id-type="pmid">15752439</pub-id></mixed-citation></ref><ref id="pone.0223017.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Berthet</surname><given-names>FX</given-names></name>, <name><surname>Zeller</surname><given-names>HG</given-names></name>, <name><surname>Drouet</surname><given-names>MT</given-names></name>, <name><surname>Rauzier</surname><given-names>J</given-names></name>, <name><surname>Digoutte</surname><given-names>JP</given-names></name>, <name><surname>Deubel</surname><given-names>V</given-names></name>. <article-title>Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses</article-title>. <source>J Gen Virol</source>. <year>1997</year>;<volume>78</volume> (<issue>Pt 9</issue>):<fpage>2293</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-78-9-2293</pub-id> .<?supplied-pmid 9292017?><pub-id pub-id-type="pmid">9292017</pub-id></mixed-citation></ref><ref id="pone.0223017.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Costa</surname><given-names>SM</given-names></name>, <name><surname>Azevedo</surname><given-names>AS</given-names></name>, <name><surname>Paes</surname><given-names>MV</given-names></name>, <name><surname>Sarges</surname><given-names>FS</given-names></name>, <name><surname>Freire</surname><given-names>MS</given-names></name>, <name><surname>Alves</surname><given-names>AM</given-names></name>. <article-title>DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice</article-title>. <source>Virology</source>. <year>2007</year>;<volume>358</volume>(<issue>2</issue>):<fpage>413</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2006.08.052</pub-id> .<?supplied-pmid 17020777?><pub-id pub-id-type="pmid">17020777</pub-id></mixed-citation></ref><ref id="pone.0223017.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Teo</surname><given-names>KF</given-names></name>, <name><surname>Wright</surname><given-names>PJ</given-names></name>. <article-title>Internal proteolysis of the NS3 protein specified by dengue virus 2</article-title>. <source>J Gen Virol</source>. <year>1997</year>;<volume>78</volume> (<issue>Pt 2</issue>):<fpage>337</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-78-2-337</pub-id> .<?supplied-pmid 9018055?><pub-id pub-id-type="pmid">9018055</pub-id></mixed-citation></ref><ref id="pone.0223017.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Oliveira</surname><given-names>AS</given-names></name>, <name><surname>Silva</surname><given-names>ML</given-names></name>, <name><surname>Oliveira</surname><given-names>AFCS</given-names></name>, <name><surname>Silva</surname><given-names>CC</given-names></name>, <name><surname>Teixeira</surname><given-names>RR</given-names></name>, <name><surname>Paula</surname><given-names>SOD</given-names></name>. <article-title>NS3 and NS5 proteins: important targets for anti-dengue drug design</article-title>. <source>J Braz Chem Soc</source>. <year>2014</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1759</fpage>&#x02013;<lpage>69</lpage>.</mixed-citation></ref><ref id="pone.0223017.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Noble</surname><given-names>CG</given-names></name>, <name><surname>Chen</surname><given-names>YL</given-names></name>, <name><surname>Dong</surname><given-names>H</given-names></name>, <name><surname>Gu</surname><given-names>F</given-names></name>, <name><surname>Lim</surname><given-names>SP</given-names></name>, <name><surname>Schul</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Strategies for development of Dengue virus inhibitors</article-title>. <source>Antiviral Res</source>. <year>2010</year>;<volume>85</volume>(<issue>3</issue>):<fpage>450</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.12.011</pub-id> .<?supplied-pmid 20060421?><pub-id pub-id-type="pmid">20060421</pub-id></mixed-citation></ref><ref id="pone.0223017.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>SP</given-names></name>, <name><surname>Wang</surname><given-names>QY</given-names></name>, <name><surname>Noble</surname><given-names>CG</given-names></name>, <name><surname>Chen</surname><given-names>YL</given-names></name>, <name><surname>Dong</surname><given-names>H</given-names></name>, <name><surname>Zou</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Ten years of dengue drug discovery: progress and prospects</article-title>. <source>Antiviral Res</source>. <year>2013</year>;<volume>100</volume>(<issue>2</issue>):<fpage>500</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.09.013</pub-id> .<?supplied-pmid 24076358?><pub-id pub-id-type="pmid">24076358</pub-id></mixed-citation></ref><ref id="pone.0223017.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>T</given-names></name>, <name><surname>Sampath</surname><given-names>A</given-names></name>, <name><surname>Chao</surname><given-names>A</given-names></name>, <name><surname>Wen</surname><given-names>D</given-names></name>, <name><surname>Nanao</surname><given-names>M</given-names></name>, <name><surname>Chene</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 A</article-title>. <source>J Virol</source>. <year>2005</year>;<volume>79</volume>(<issue>16</issue>):<fpage>10278</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.16.10278-10288.2005</pub-id>
<?supplied-pmid 16051821?><pub-id pub-id-type="pmid">16051821</pub-id></mixed-citation></ref><ref id="pone.0223017.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Lescar</surname><given-names>J</given-names></name>, <name><surname>Luo</surname><given-names>D</given-names></name>, <name><surname>Xu</surname><given-names>T</given-names></name>, <name><surname>Sampath</surname><given-names>A</given-names></name>, <name><surname>Lim</surname><given-names>SP</given-names></name>, <name><surname>Canard</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target</article-title>. <source>Antiviral Res</source>. <year>2008</year>;<volume>80</volume>(<issue>2</issue>):<fpage>94</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2008.07.001</pub-id> .<?supplied-pmid 18674567?><pub-id pub-id-type="pmid">18674567</pub-id></mixed-citation></ref><ref id="pone.0223017.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Yoganathan</surname><given-names>K</given-names></name>, <name><surname>Rossant</surname><given-names>C</given-names></name>, <name><surname>Ng</surname><given-names>S</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Butler</surname><given-names>MS</given-names></name>, <name><surname>Buss</surname><given-names>AD</given-names></name>. <article-title>10-Methoxydihydrofuscin, fuscinarin, and fuscin, novel antagonists of the human CCR5 receptor from Oidiodendron griseum</article-title>. <source>J Nat Prod</source>. <year>2003</year>;<volume>66</volume>(<issue>8</issue>):<fpage>1116</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1021/np030146m</pub-id> .<?supplied-pmid 12932138?><pub-id pub-id-type="pmid">12932138</pub-id></mixed-citation></ref><ref id="pone.0223017.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Aravapalli</surname><given-names>S</given-names></name>, <name><surname>Lai</surname><given-names>H</given-names></name>, <name><surname>Teramoto</surname><given-names>T</given-names></name>, <name><surname>Alliston</surname><given-names>KR</given-names></name>, <name><surname>Lushington</surname><given-names>GH</given-names></name>, <name><surname>Ferguson</surname><given-names>EL</given-names></name>, <etal>et al</etal>
<article-title>Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold</article-title>. <source>Bioorg Med Chem</source>. <year>2012</year>;<volume>20</volume>(<issue>13</issue>):<fpage>4140</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2012.04.055</pub-id>
<?supplied-pmid 22632792?><pub-id pub-id-type="pmid">22632792</pub-id></mixed-citation></ref><ref id="pone.0223017.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Tiew</surname><given-names>KC</given-names></name>, <name><surname>Dou</surname><given-names>D</given-names></name>, <name><surname>Teramoto</surname><given-names>T</given-names></name>, <name><surname>Lai</surname><given-names>H</given-names></name>, <name><surname>Alliston</surname><given-names>KR</given-names></name>, <name><surname>Lushington</surname><given-names>GH</given-names></name>, <etal>et al</etal>
<article-title>Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives</article-title>. <source>Bioorg Med Chem</source>. <year>2012</year>;<volume>20</volume>(<issue>3</issue>):<fpage>1213</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2011.12.047</pub-id>
<?supplied-pmid 22249124?><pub-id pub-id-type="pmid">22249124</pub-id></mixed-citation></ref><ref id="pone.0223017.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Tragoolpua</surname><given-names>Y</given-names></name>, <name><surname>Jatisatienr</surname><given-names>A</given-names></name>. <article-title>Anti-herpes simplex virus activities of Eugenia caryophyllus (Spreng.) Bullock &#x00026; S. G. Harrison and essential oil, eugenol.</article-title>
<source>Phytother Res</source>. <year>2007</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1153</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.2226</pub-id> .<?supplied-pmid 17628885?><pub-id pub-id-type="pmid">17628885</pub-id></mixed-citation></ref><ref id="pone.0223017.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Benencia</surname><given-names>F</given-names></name>, <name><surname>Courreges</surname><given-names>MC</given-names></name>. <article-title>In vitro and in vivo activity of eugenol on human herpesvirus</article-title>. <source>Phytother Res</source>. <year>2000</year>;<volume>14</volume>(<issue>7</issue>):<fpage>495</fpage>&#x02013;<lpage>500</lpage>. .<?supplied-pmid 11054837?><pub-id pub-id-type="pmid">11054837</pub-id></mixed-citation></ref><ref id="pone.0223017.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Serkedjieva</surname><given-names>J</given-names></name>, <name><surname>Ivancheva</surname><given-names>S</given-names></name>. <article-title>Antiherpes virus activity of extracts from the medicinal plant Geranium sanguineum L</article-title>. <source>J Ethnopharmacol</source>. <year>1999</year>;<volume>64</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/s0378-8741(98)00095-6</pub-id> .<?supplied-pmid 10075123?><pub-id pub-id-type="pmid">10075123</pub-id></mixed-citation></ref><ref id="pone.0223017.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Dai</surname><given-names>JP</given-names></name>, <name><surname>Zhao</surname><given-names>XF</given-names></name>, <name><surname>Zeng</surname><given-names>J</given-names></name>, <name><surname>Wan</surname><given-names>QY</given-names></name>, <name><surname>Yang</surname><given-names>JC</given-names></name>, <name><surname>Li</surname><given-names>WZ</given-names></name>, <etal>et al</etal>
<article-title>Drug screening for autophagy inhibitors based on the dissociation of Beclin1-Bcl2 complex using BiFC technique and mechanism of eugenol on anti-influenza A virus activity.</article-title>
<source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e61026</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0061026</pub-id>
<?supplied-pmid 23613775?><pub-id pub-id-type="pmid">23613775</pub-id></mixed-citation></ref><ref id="pone.0223017.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Bondre</surname><given-names>VP</given-names></name>, <name><surname>Jadi</surname><given-names>RS</given-names></name>, <name><surname>Mishra</surname><given-names>AC</given-names></name>, <name><surname>Yergolkar</surname><given-names>PN</given-names></name>, <name><surname>Arankalle</surname><given-names>VA</given-names></name>. <article-title>West Nile virus isolates from India: evidence for a distinct genetic lineage</article-title>. <source>J Gen Virol</source>. <year>2007</year>;<volume>88</volume>(<issue>Pt 3</issue>):<fpage>875</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.82403-0</pub-id> .<?supplied-pmid 17325360?><pub-id pub-id-type="pmid">17325360</pub-id></mixed-citation></ref><ref id="pone.0223017.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Behnam</surname><given-names>MA</given-names></name>, <name><surname>Nitsche</surname><given-names>C</given-names></name>, <name><surname>Boldescu</surname><given-names>V</given-names></name>, <name><surname>Klein</surname><given-names>CD</given-names></name>. <article-title>The Medicinal Chemistry of Dengue Virus</article-title>. <source>J Med Chem</source>. <year>2016</year>;<volume>59</volume>(<issue>12</issue>):<fpage>5622</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01653</pub-id> .<?supplied-pmid 26771861?><pub-id pub-id-type="pmid">26771861</pub-id></mixed-citation></ref><ref id="pone.0223017.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Weigel</surname><given-names>LF</given-names></name>, <name><surname>Nitsche</surname><given-names>C</given-names></name>, <name><surname>Graf</surname><given-names>D</given-names></name>, <name><surname>Bartenschlager</surname><given-names>R</given-names></name>, <name><surname>Klein</surname><given-names>CD</given-names></name>. <article-title>Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors</article-title>. <source>J Med Chem</source>. <year>2015</year>;<volume>58</volume>(<issue>19</issue>):<fpage>7719</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00612</pub-id> .<?supplied-pmid 26367391?><pub-id pub-id-type="pmid">26367391</pub-id></mixed-citation></ref><ref id="pone.0223017.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Timiri</surname><given-names>AK</given-names></name>, <name><surname>Sinha</surname><given-names>BN</given-names></name>, <name><surname>Jayaprakash</surname><given-names>V</given-names></name>. <article-title>Progress and prospects on DENV protease inhibitors</article-title>. <source>Eur J Med Chem</source>. <year>2016</year>;<volume>117</volume>:<fpage>125</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2016.04.008</pub-id> .<?supplied-pmid 27092412?><pub-id pub-id-type="pmid">27092412</pub-id></mixed-citation></ref><ref id="pone.0223017.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>XZ</given-names></name>, <name><surname>Zhu</surname><given-names>Y</given-names></name>, <name><surname>Guan</surname><given-names>XL</given-names></name>, <name><surname>Tian</surname><given-names>K</given-names></name>, <name><surname>Guo</surname><given-names>JM</given-names></name>, <name><surname>Wang</surname><given-names>HB</given-names></name>, <etal>et al</etal>
<article-title>A novel antioxidant isobenzofuranone derivative from fungus Cephalosporium sp.AL031</article-title>. <source>Molecules</source>. <year>2012</year>;<volume>17</volume>(<issue>4</issue>):<fpage>4219</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.3390/molecules17044219</pub-id> .<?supplied-pmid 22481542?><pub-id pub-id-type="pmid">22481542</pub-id></mixed-citation></ref><ref id="pone.0223017.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Strobel</surname><given-names>G</given-names></name>, <name><surname>Ford</surname><given-names>E</given-names></name>, <name><surname>Worapong</surname><given-names>J</given-names></name>, <name><surname>Harper</surname><given-names>JK</given-names></name>, <name><surname>Arif</surname><given-names>AM</given-names></name>, <name><surname>Grant</surname><given-names>DM</given-names></name>, <etal>et al</etal>
<article-title>Isopestacin, an isobenzofuranone from Pestalotiopsis microspora, possessing antifungal and antioxidant activities</article-title>. <source>Phytochemistry</source>. <year>2002</year>;<volume>60</volume>(<issue>2</issue>):<fpage>179</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/s0031-9422(02)00062-6</pub-id> .<?supplied-pmid 12009322?><pub-id pub-id-type="pmid">12009322</pub-id></mixed-citation></ref><ref id="pone.0223017.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Peng</surname><given-names>Y</given-names></name>, <name><surname>Zeng</surname><given-names>X</given-names></name>, <name><surname>Feng</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>. <article-title>Antiplatelet and antithrombotic activity of L-3-n-butylphthalide in rats</article-title>. <source>J Cardiovasc Pharmacol</source>. <year>2004</year>;<volume>43</volume>(<issue>6</issue>):<fpage>876</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1097/00005344-200406000-00018</pub-id> .<?supplied-pmid 15167282?><pub-id pub-id-type="pmid">15167282</pub-id></mixed-citation></ref><ref id="pone.0223017.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Hu</surname><given-names>GY</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>ZH</given-names></name>. <article-title>Synthesis, resolution, and antiplatelet activity of 3-substituted 1(3H)-isobenzofuranone</article-title>. <source>Bioorg Med Chem Lett</source>. <year>2007</year>;<volume>17</volume>(<issue>18</issue>):<fpage>5210</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.06.082</pub-id> .<?supplied-pmid 17632002?><pub-id pub-id-type="pmid">17632002</pub-id></mixed-citation></ref><ref id="pone.0223017.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>F</given-names></name>, <name><surname>Gao</surname><given-names>Y</given-names></name>, <name><surname>Qiao</surname><given-names>H</given-names></name>, <name><surname>Hu</surname><given-names>X</given-names></name>, <name><surname>Chang</surname><given-names>J</given-names></name>. <article-title>Antiplatelet activity of 3-butyl-6-bromo-1(3H)-isobenzofuranone on rat platelet aggregation.</article-title>
<source>J Thromb Thrombolysis</source>. <year>2012</year>;<volume>33</volume>(<issue>1</issue>):<fpage>64</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1007/s11239-011-0647-9</pub-id> .<?supplied-pmid 22057435?><pub-id pub-id-type="pmid">22057435</pub-id></mixed-citation></ref><ref id="pone.0223017.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Cardozo</surname><given-names>JAB-F</given-names></name>, <name><surname>Raimudo</surname></name>; <name><surname>Javier</surname><given-names>Rinc&#x000f3;n-Velandia</given-names></name>; <name><surname>Guerrero-Pab&#x000f3;n</surname></name>, <name><surname>Mario</surname><given-names>F</given-names></name>. <article-title>3-Buthyl-isobenzofuranone: a compound isolated from Apium graveolens with anticonvulsant activity.</article-title>
<source>Rev Colomb Ciencias Quim Farm</source>. <year>2005</year>;<volume>34</volume>(<issue>1</issue>):<fpage>69</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref><ref id="pone.0223017.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Teixeira</surname><given-names>RR</given-names></name>, <name><surname>Bressan</surname><given-names>GC</given-names></name>, <name><surname>Pereira</surname><given-names>WL</given-names></name>, <name><surname>Ferreira</surname><given-names>JG</given-names></name>, <name><surname>de Oliveira</surname><given-names>FM</given-names></name>, <name><surname>Thomaz</surname><given-names>DC</given-names></name>. <article-title>Synthesis and antiproliferative activity of C-3 functionalized isobenzofuran-1(3H)-ones.</article-title>
<source>Molecules</source>. <year>2013</year>;<volume>18</volume>(<issue>2</issue>):<fpage>1881</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.3390/molecules18021881</pub-id> .<?supplied-pmid 23377131?><pub-id pub-id-type="pmid">23377131</pub-id></mixed-citation></ref><ref id="pone.0223017.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Artico</surname><given-names>M</given-names></name>, <name><surname>Di Santo</surname><given-names>R</given-names></name>, <name><surname>Costi</surname><given-names>R</given-names></name>, <name><surname>Novellino</surname><given-names>E</given-names></name>, <name><surname>Greco</surname><given-names>G</given-names></name>, <name><surname>Massa</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling</article-title>. <source>J Med Chem</source>. <year>1998</year>;<volume>41</volume>(<issue>21</issue>):<fpage>3948</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1021/jm9707232</pub-id> .<?supplied-pmid 9767632?><pub-id pub-id-type="pmid">9767632</pub-id></mixed-citation></ref><ref id="pone.0223017.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Goudreau</surname><given-names>N</given-names></name>, <name><surname>Cameron</surname><given-names>DR</given-names></name>, <name><surname>Deziel</surname><given-names>R</given-names></name>, <name><surname>Hache</surname><given-names>B</given-names></name>, <name><surname>Jakalian</surname><given-names>A</given-names></name>, <name><surname>Malenfant</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach</article-title>. <source>Bioorg Med Chem</source>. <year>2007</year>;<volume>15</volume>(<issue>7</issue>):<fpage>2690</fpage>&#x02013;<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2007.01.036</pub-id> .<?supplied-pmid 17306550?><pub-id pub-id-type="pmid">17306550</pub-id></mixed-citation></ref><ref id="pone.0223017.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Davidson</surname><given-names>W</given-names></name>, <name><surname>McGibbon</surname><given-names>GA</given-names></name>, <name><surname>White</surname><given-names>PW</given-names></name>, <name><surname>Yoakim</surname><given-names>C</given-names></name>, <name><surname>Hopkins</surname><given-names>JL</given-names></name>, <name><surname>Guse</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Characterization of the binding site for inhibitors of the HPV11 E1-E2 protein interaction on the E2 transactivation domain by photoaffinity labeling and mass spectrometry</article-title>. <source>Anal Chem</source>. <year>2004</year>;<volume>76</volume>(<issue>7</issue>):<fpage>2095</fpage>&#x02013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1021/ac035335o</pub-id> .<?supplied-pmid 15053675?><pub-id pub-id-type="pmid">15053675</pub-id></mixed-citation></ref><ref id="pone.0223017.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Yoakim</surname><given-names>C</given-names></name>, <name><surname>Ogilvie</surname><given-names>WW</given-names></name>, <name><surname>Goudreau</surname><given-names>N</given-names></name>, <name><surname>Naud</surname><given-names>J</given-names></name>, <name><surname>Hache</surname><given-names>B</given-names></name>, <name><surname>O'Meara</surname><given-names>JA</given-names></name>, <etal>et al</etal>
<article-title>Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex</article-title>. <source>Bioorg Med Chem Lett</source>. <year>2003</year>;<volume>13</volume>(<issue>15</issue>):<fpage>2539</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/s0960-894x(03)00510-9</pub-id> .<?supplied-pmid 12852961?><pub-id pub-id-type="pmid">12852961</pub-id></mixed-citation></ref><ref id="pone.0223017.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Saldivar</surname><given-names>A</given-names></name>, <name><surname>Bess</surname><given-names>J</given-names></name>, <name><surname>Solomon</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>CM</given-names></name>, <name><surname>Tripathi</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Investigating the origin of the slow-binding inhibition of HCV NS3 serine protease by a novel substrate based inhibitor</article-title>. <source>Biochemistry</source>. <year>2003</year>;<volume>42</volume>(<issue>29</issue>):<fpage>8862</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1021/bi034661v</pub-id> .<?supplied-pmid 12873147?><pub-id pub-id-type="pmid">12873147</pub-id></mixed-citation></ref><ref id="pone.0223017.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Oliveira</surname><given-names>A</given-names></name>, <name><surname>de Souza</surname><given-names>APM</given-names></name>, <name><surname>de Oliveira</surname><given-names>AS</given-names></name>, <name><surname>da Silva</surname><given-names>ML</given-names></name>, <name><surname>de Oliveira</surname><given-names>FM</given-names></name>, <name><surname>Santos</surname><given-names>EG</given-names></name>, <etal>et al</etal>
<article-title>Zirconium catalyzed synthesis of 2-arylidene Indan-1,3-diones and evaluation of their inhibitory activity against NS2B-NS3 WNV protease</article-title>. <source>Eur J Med Chem</source>. <year>2018</year>;<volume>149</volume>:<fpage>98</fpage>&#x02013;<lpage>109</lpage>. Epub 2018/03/03. <pub-id pub-id-type="doi">10.1016/j.ejmech.2018.02.037</pub-id> .<?supplied-pmid 29499491?><pub-id pub-id-type="pmid">29499491</pub-id></mixed-citation></ref><ref id="pone.0223017.ref042"><label>42</label><mixed-citation publication-type="book"><name><surname>Perrin</surname><given-names>DD</given-names></name>, <name><surname>Armarego</surname><given-names>WLF</given-names></name>. <source>Purification of Laboratory Chemicals.</source>
<edition>3rd edn</edition> ed. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Pergamon</publisher-name>; <year>1988</year>.</mixed-citation></ref><ref id="pone.0223017.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>da Silva Maia</surname><given-names>AF</given-names></name>, <name><surname>Siqueira</surname><given-names>RP</given-names></name>, <name><surname>de Oliveira</surname><given-names>FM</given-names></name>, <name><surname>Ferreira</surname><given-names>JG</given-names></name>, <name><surname>da Silva</surname><given-names>SF</given-names></name>, <name><surname>Caiuby</surname><given-names>CAD</given-names></name>, <etal>et al</etal>
<article-title>Synthesis, molecular properties prediction and cytotoxic screening of 3-(2-aryl-2-oxoethyl)isobenzofuran-1(3H)-ones.</article-title>
<source>Bioorg Med Chem Lett</source>. <year>2016</year>;<volume>26</volume>(<issue>12</issue>):<fpage>2810</fpage>&#x02013;<lpage>6</lpage>. Epub 2016/05/09. <pub-id pub-id-type="doi">10.1016/j.bmcl.2016.04.065</pub-id> .<?supplied-pmid 27155902?><pub-id pub-id-type="pmid">27155902</pub-id></mixed-citation></ref><ref id="pone.0223017.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Mosmann</surname><given-names>T.</given-names></name>
<article-title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</article-title>. <source>J Immunol Methods</source>. <year>1983</year>;<volume>65</volume>(<issue>1&#x02013;2</issue>):<fpage>55</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/0022-1759(83)90303-4</pub-id> .<?supplied-pmid 6606682?><pub-id pub-id-type="pmid">6606682</pub-id></mixed-citation></ref><ref id="pone.0223017.ref045"><label>45</label><mixed-citation publication-type="other">LigPrep SR. 3.4.014 ed. New York: Schrodinger, LLC; 2016.</mixed-citation></ref><ref id="pone.0223017.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Aleshin</surname><given-names>AE</given-names></name>, <name><surname>Shiryaev</surname><given-names>SA</given-names></name>, <name><surname>Strongin</surname><given-names>AY</given-names></name>, <name><surname>Liddington</surname><given-names>RC</given-names></name>. <article-title>Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold</article-title>. <source>Protein Sci</source>. <year>2007</year>;<volume>16</volume>(<issue>5</issue>):<fpage>795</fpage>&#x02013;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1110/ps.072753207</pub-id>
<?supplied-pmid 17400917?><pub-id pub-id-type="pmid">17400917</pub-id></mixed-citation></ref><ref id="pone.0223017.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Friesner</surname><given-names>RA</given-names></name>, <name><surname>Banks</surname><given-names>JL</given-names></name>, <name><surname>Murphy</surname><given-names>RB</given-names></name>, <name><surname>Halgren</surname><given-names>TA</given-names></name>, <name><surname>Klicic</surname><given-names>JJ</given-names></name>, <name><surname>Mainz</surname><given-names>DT</given-names></name>, <etal>et al</etal>
<article-title>Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</article-title>. <source>J Med Chem</source>. <year>2004</year>;<volume>47</volume>(<issue>7</issue>):<fpage>1739</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1021/jm0306430</pub-id> .<?supplied-pmid 15027865?><pub-id pub-id-type="pmid">15027865</pub-id></mixed-citation></ref><ref id="pone.0223017.ref048"><label>48</label><mixed-citation publication-type="other">Schr&#x000f6;dinger. Glide. New York: Schr&#x000f6;dinger, LLC; 2016.</mixed-citation></ref><ref id="pone.0223017.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Sherman</surname><given-names>W</given-names></name>, <name><surname>Day</surname><given-names>T</given-names></name>, <name><surname>Jacobson</surname><given-names>MP</given-names></name>, <name><surname>Friesner</surname><given-names>RA</given-names></name>, <name><surname>Farid</surname><given-names>R</given-names></name>. <article-title>Novel procedure for modeling ligand/receptor induced fit effects</article-title>. <source>J Med Chem</source>. <year>2006</year>;<volume>49</volume>(<issue>2</issue>):<fpage>534</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1021/jm050540c</pub-id> .<?supplied-pmid 16420040?><pub-id pub-id-type="pmid">16420040</pub-id></mixed-citation></ref><ref id="pone.0223017.ref050"><label>50</label><mixed-citation publication-type="other">Schr&#x000f6;dinger. Schr&#x000f6;dinger Release. New york: Schr&#x000f6;dinger, LLC; 2016.</mixed-citation></ref><ref id="pone.0223017.ref051"><label>51</label><mixed-citation publication-type="other">Schr&#x000f6;dinger. Maestro. 10.6 ed. New York: Schr&#x000f6;dinger, LLC; 2016.</mixed-citation></ref><ref id="pone.0223017.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Borgati</surname><given-names>TF</given-names></name>, <name><surname>Alves</surname><given-names>RB</given-names></name>, <name><surname>Teixeira</surname><given-names>RR</given-names></name>, <name><surname>Freitas</surname><given-names>RPd</given-names></name>, <name><surname>Perdig&#x000e3;o</surname><given-names>TG</given-names></name>, <name><surname>Silva</surname><given-names>SFd</given-names></name>, <etal>et al</etal>
<article-title>Synthesis and phytotoxic activity of 1,2,3-triazole derivatives</article-title>. <source>J Braz Chem Soc</source>. <year>2013</year>;<volume>24</volume>:<fpage>953</fpage>&#x02013;<lpage>61</lpage>.</mixed-citation></ref><ref id="pone.0223017.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Balasubramanian</surname><given-names>A</given-names></name>, <name><surname>Manzano</surname><given-names>M</given-names></name>, <name><surname>Teramoto</surname><given-names>T</given-names></name>, <name><surname>Pilankatta</surname><given-names>R</given-names></name>, <name><surname>Padmanabhan</surname><given-names>R</given-names></name>. <article-title>High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease</article-title>. <source>Antiviral Res</source>. <year>2016</year>;<volume>134</volume>:<fpage>6</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.08.014</pub-id>
<?supplied-pmid 27539384?><pub-id pub-id-type="pmid">27539384</pub-id></mixed-citation></ref><ref id="pone.0223017.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>D</given-names></name>, <name><surname>Vasudevan</surname><given-names>SG</given-names></name>, <name><surname>Lescar</surname><given-names>J</given-names></name>. <article-title>The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development</article-title>. <source>Antiviral Res</source>. <year>2015</year>;<volume>118</volume>:<fpage>148</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.03.014</pub-id> .<?supplied-pmid 25842996?><pub-id pub-id-type="pmid">25842996</pub-id></mixed-citation></ref><ref id="pone.0223017.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>M</given-names></name>, <name><surname>Lee</surname><given-names>EM</given-names></name>, <name><surname>Wen</surname><given-names>Z</given-names></name>, <name><surname>Cheng</surname><given-names>Y</given-names></name>, <name><surname>Huang</surname><given-names>WK</given-names></name>, <name><surname>Qian</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</article-title>. <source>Nat Med</source>. <year>2016</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1101</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4184</pub-id> .<?supplied-pmid 27571349?><pub-id pub-id-type="pmid">27571349</pub-id></mixed-citation></ref><ref id="pone.0223017.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Khalilzadeh</surname><given-names>E</given-names></name>, <name><surname>Hazrati</surname><given-names>R</given-names></name>, <name><surname>Saiah</surname><given-names>GV</given-names></name>. <article-title>Effects of topical and systemic administration of Eugenia caryophyllata buds essential oil on corneal anesthesia and analgesia</article-title>. <source>Res Pharm Sci</source>. <year>2016</year>;<volume>11</volume>(<issue>4</issue>):<fpage>293</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.4103/1735-5362.189297</pub-id>
<?supplied-pmid 27651809?><pub-id pub-id-type="pmid">27651809</pub-id></mixed-citation></ref><ref id="pone.0223017.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Kildeaa</surname><given-names>MA</given-names></name>, GL GLA, <name><surname>Kearney</surname><given-names>RE</given-names></name>. <article-title>Accumulation and clearance of the anaesthetics clove oil and AQUI-S from the edible tissue of silver perch (Bidyanus bidyanus)</article-title>
<source>Aquaculture</source>. <year>2004</year>;<volume>232</volume>:<fpage>265</fpage>&#x02013;<lpage>77</lpage>.</mixed-citation></ref><ref id="pone.0223017.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Daniel</surname><given-names>AN</given-names></name>, <name><surname>Sartoretto</surname><given-names>SM</given-names></name>, <name><surname>Schmidt</surname><given-names>G</given-names></name>, <name><surname>Caparroz-Assef</surname><given-names>SM</given-names></name>, <name><surname>Bersani-Amado</surname><given-names>CA</given-names></name>, <name><surname>Cuman</surname><given-names>RKN</given-names></name>. <article-title>Anti- inflammatory and antinociceptive activities A of eugenol essential oil in experimental animal models</article-title>. <source>Rev Bras Farmacogn</source>. <year>2009</year>;<volume>19</volume>:<fpage>212</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0223017.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Kurian</surname><given-names>R</given-names></name>, <name><surname>Arulmozhi</surname><given-names>DK</given-names></name>, <name><surname>Veeranjaneyulu</surname><given-names>A</given-names></name>, <name><surname>Bodhankar</surname><given-names>SL</given-names></name>. <article-title>Effect of eugenol on animal models of nociception.</article-title>
<source>Indian J of Pharmacol</source>. <year>2006</year>;<volume>38</volume>:<fpage>341</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0223017.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Lionnet</surname><given-names>L</given-names></name>, <name><surname>Beaudry</surname><given-names>F</given-names></name>, <name><surname>Vachon</surname><given-names>P</given-names></name>. <article-title>Intrathecal eugenol administration alleviates neuropathic pain in male Sprague-Dawley rats</article-title>. <source>Phytother Res</source>. <year>2010</year>;<volume>24</volume>(<issue>11</issue>):<fpage>1645</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.3174</pub-id> .<?supplied-pmid 21031622?><pub-id pub-id-type="pmid">21031622</pub-id></mixed-citation></ref><ref id="pone.0223017.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Ohkubo</surname><given-names>T</given-names></name>, <name><surname>Shibata</surname><given-names>M</given-names></name>. <article-title>The selective capsaicin antagonist capsazepine abolishes the antinociceptive action of eugenol and guaiacol</article-title>. <source>J Dent Res</source>. <year>1997</year>;<volume>76</volume>(<issue>4</issue>):<fpage>848</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1177/00220345970760040501</pub-id> .<?supplied-pmid 9126180?><pub-id pub-id-type="pmid">9126180</pub-id></mixed-citation></ref><ref id="pone.0223017.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>SH</given-names></name>, <name><surname>Sim</surname><given-names>YB</given-names></name>, <name><surname>Lee</surname><given-names>JK</given-names></name>, <name><surname>Kim</surname><given-names>SM</given-names></name>, <name><surname>Kang</surname><given-names>YJ</given-names></name>, <name><surname>Jung</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>The analgesic effects and mechanisms of orally administered eugenol</article-title>. <source>Arch Pharm Res</source>. <year>2011</year>;<volume>34</volume>(<issue>3</issue>):<fpage>501</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-011-0320-z</pub-id> .<?supplied-pmid 21547684?><pub-id pub-id-type="pmid">21547684</pub-id></mixed-citation></ref><ref id="pone.0223017.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Islamuddin</surname><given-names>M</given-names></name>, <name><surname>Chouhan</surname><given-names>G</given-names></name>, <name><surname>Want</surname><given-names>MY</given-names></name>, <name><surname>Ozbak</surname><given-names>HA</given-names></name>, <name><surname>Hemeg</surname><given-names>HA</given-names></name>, <name><surname>Afrin</surname><given-names>F</given-names></name>. <article-title>Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2016</year>;<volume>10</volume>(<issue>10</issue>):<fpage>e0005011</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0005011</pub-id>
<?supplied-pmid 27776125?><pub-id pub-id-type="pmid">27776125</pub-id></mixed-citation></ref><ref id="pone.0223017.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Fujisawa</surname><given-names>S</given-names></name>, <name><surname>Murakami</surname><given-names>Y</given-names></name>. <article-title>Eugenol and Its Role in Chronic Diseases</article-title>. <source>Adv Exp Med Biol</source>. <year>2016</year>;<volume>929</volume>:<fpage>45</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-41342-6_3</pub-id> .<?supplied-pmid 27771920?><pub-id pub-id-type="pmid">27771920</pub-id></mixed-citation></ref><ref id="pone.0223017.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Mahadlek</surname><given-names>J</given-names></name>, <name><surname>Charoenteeraboon</surname><given-names>J</given-names></name>, <name><surname>Phaechamud</surname><given-names>T</given-names></name>. <article-title>Zinc Oxide Gels for periodontitis treatment</article-title>. <source>J Metal Mater Mineral</source>. <year>2010</year>;<volume>20</volume>:<fpage>159</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="pone.0223017.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Tanaka</surname><given-names>S</given-names></name>, <name><surname>Royds</surname><given-names>C</given-names></name>, <name><surname>Buckley</surname><given-names>D</given-names></name>, <name><surname>Basketter</surname><given-names>DA</given-names></name>, <name><surname>Goossens</surname><given-names>A</given-names></name>, <name><surname>Bruze</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Contact allergy to isoeugenol and its derivatives: problems with allergen substitution</article-title>. <source>Contact Dermatitis</source>. <year>2004</year>;<volume>51</volume>(<issue>5&#x02013;6</issue>):<fpage>288</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1111/j.0105-1873.2004.00446.x</pub-id> .<?supplied-pmid 15606655?><pub-id pub-id-type="pmid">15606655</pub-id></mixed-citation></ref><ref id="pone.0223017.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Lei</surname><given-names>J</given-names></name>, <name><surname>Hansen</surname><given-names>G</given-names></name>, <name><surname>Nitsche</surname><given-names>C</given-names></name>, <name><surname>Klein</surname><given-names>CD</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Hilgenfeld</surname><given-names>R</given-names></name>. <article-title>Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor</article-title>. <source>Science</source>. <year>2016</year>;<volume>353</volume>(<issue>6298</issue>):<fpage>503</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.aag2419</pub-id> .<?supplied-pmid 27386922?><pub-id pub-id-type="pmid">27386922</pub-id></mixed-citation></ref><ref id="pone.0223017.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Noble</surname><given-names>CG</given-names></name>, <name><surname>Seh</surname><given-names>CC</given-names></name>, <name><surname>Chao</surname><given-names>AT</given-names></name>, <name><surname>Shi</surname><given-names>PY</given-names></name>. <article-title>Ligand-bound structures of the dengue virus protease reveal the active conformation</article-title>. <source>J Virol</source>. <year>2012</year>;<volume>86</volume>(<issue>1</issue>):<fpage>438</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.06225-11</pub-id>
<?supplied-pmid 22031935?><pub-id pub-id-type="pmid">22031935</pub-id></mixed-citation></ref><ref id="pone.0223017.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Erbel</surname><given-names>P</given-names></name>, <name><surname>Schiering</surname><given-names>N</given-names></name>, <name><surname>D'Arcy</surname><given-names>A</given-names></name>, <name><surname>Renatus</surname><given-names>M</given-names></name>, <name><surname>Kroemer</surname><given-names>M</given-names></name>, <name><surname>Lim</surname><given-names>SP</given-names></name>, <etal>et al</etal>
<article-title>Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus</article-title>. <source>Nat Struct Mol Biol</source>. <year>2006</year>;<volume>13</volume>(<issue>4</issue>):<fpage>372</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb1073</pub-id> .<?supplied-pmid 16532006?><pub-id pub-id-type="pmid">16532006</pub-id></mixed-citation></ref><ref id="pone.0223017.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Robin</surname><given-names>G</given-names></name>, <name><surname>Chappell</surname><given-names>K</given-names></name>, <name><surname>Stoermer</surname><given-names>MJ</given-names></name>, <name><surname>Hu</surname><given-names>SH</given-names></name>, <name><surname>Young</surname><given-names>PR</given-names></name>, <name><surname>Fairlie</surname><given-names>DP</given-names></name>, <etal>et al</etal>
<article-title>Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation</article-title>. <source>J Mol Biol</source>. <year>2009</year>;<volume>385</volume>(<issue>5</issue>):<fpage>1568</fpage>&#x02013;<lpage>77</lpage>. Epub 2008/12/09. <pub-id pub-id-type="doi">10.1016/j.jmb.2008.11.026</pub-id> .<?supplied-pmid 19059417?><pub-id pub-id-type="pmid">19059417</pub-id></mixed-citation></ref><ref id="pone.0223017.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Hammamy</surname><given-names>MZ</given-names></name>, <name><surname>Haase</surname><given-names>C</given-names></name>, <name><surname>Hammami</surname><given-names>M</given-names></name>, <name><surname>Hilgenfeld</surname><given-names>R</given-names></name>, <name><surname>Steinmetzer</surname><given-names>T</given-names></name>. <article-title>Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease</article-title>. <source>ChemMedChem</source>. <year>2013</year>;<volume>8</volume>(<issue>2</issue>):<fpage>231</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201200497</pub-id> .<?supplied-pmid 23307694?><pub-id pub-id-type="pmid">23307694</pub-id></mixed-citation></ref><ref id="pone.0223017.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Nitsche</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Weigel</surname><given-names>LF</given-names></name>, <name><surname>Schilz</surname><given-names>J</given-names></name>, <name><surname>Graf</surname><given-names>D</given-names></name>, <name><surname>Bartenschlager</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Peptide-Boronic Acid Inhibitors of Flaviviral Proteases: Medicinal Chemistry and Structural Biology</article-title>. <source>J Med Chem</source>. <year>2017</year>;<volume>60</volume>(<issue>1</issue>):<fpage>511</fpage>&#x02013;<lpage>6</lpage>. Epub 2016/12/15. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01021</pub-id> .<?supplied-pmid 27966962?><pub-id pub-id-type="pmid">27966962</pub-id></mixed-citation></ref></ref-list></back></article>